: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Hanzi Hunter — ultra-fast Hanzi study

All 1,152 characters from the aioLingua manual

Abstract • About • The 20 audio files

← aioLingua Chinese Online

← Chinese aioLingua PDF

Multiple Sclerosis

Free Subscription

Articles published in Mult Scler
Retrieve available abstracts of 501 articles:
HTML format

Single Articles

November 2025

SHI Z, Wang H, Yan Z, Tang Y, et al
T1-based stratification of paramagnetic rim lesions in multiple sclerosis: Evidence of microstructural heterogeneity and clinical implications.
Mult Scler. 2025 Nov 10:13524585251389809. doi: 10.1177/13524585251389809.
PubMed Abstract available

YANG JH, Race J, Sumowski P, Jacques K, et al
Epigenetic age and telomere length correlations in pediatric-onset multiple sclerosis.
Mult Scler. 2025 Nov 6:13524585251386217. doi: 10.1177/13524585251386217.
PubMed Abstract available

SELMAJ KW, Steinman L, Comi G, Bar-Or A, et al
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.
Mult Scler. 2025;31:1557-1571.
PubMed Abstract available

SANDGREN S, Maceski AM, Benkert P, Einsiedler M, et al
Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity.
Mult Scler. 2025;31:1531-1542.
PubMed Abstract available

VAN SCHEPENDOM J, Cutter G
Lost in dichotomization: Preserving statistical power and sensitivity in MS cognitive research.
Mult Scler. 2025;31:1513-1517.
PubMed Abstract available

October 2025

ZIEMSSEN T, Freedman MS, Bar-Or A, Montalban X, et al
Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis.
Mult Scler. 2025 Oct 29:13524585251389797. doi: 10.1177/13524585251389797.
PubMed Abstract available

BANKS SA, Baker MR, Flanagan EP, Permezel FE, et al
Tremor and disability outcomes following deep brain stimulation for multiple sclerosis-associated tremor.
Mult Scler. 2025 Oct 27:13524585251387935. doi: 10.1177/13524585251387935.
PubMed Abstract available

BRIGGS FB, Yang J, Toljan K, Conway DS, et al
Longitudinal modeling of upper extremity function in multiple sclerosis: Associations for clinical and sociodemographic factors.
Mult Scler. 2025 Oct 26:13524585251384060. doi: 10.1177/13524585251384060.
PubMed Abstract available

CHERTCOFF AS, Ruiz-Alguero M, Yusuf F, Zhao Y, et al
Psychiatric morbidity during the multiple sclerosis prodrome is associated with future disability.
Mult Scler. 2025 Oct 26:13524585251382801. doi: 10.1177/13524585251382801.
PubMed Abstract available

BALSHI A, Feldman TB, Dempsey JP, Baber U, et al
A multicenter cohort of transgender and gender diverse people with multiple sclerosis.
Mult Scler. 2025 Oct 8:13524585251383330. doi: 10.1177/13524585251383330.
PubMed Abstract available

BARBUTI E, Prosperini L, Ruggieri S, Haggiag S, et al
How premorbid structural reserve affects disability accrual in multiple sclerosis.
Mult Scler. 2025 Oct 8:13524585251372440. doi: 10.1177/13524585251372440.
PubMed Abstract available

BORDET C, Maachi O, Papeix AC, Laigo P, et al
Human papillomavirus-related conditions in women with multiple sclerosis receiving disease-modifying therapies: A Pharmacovigilance disproportionality analysis from the WHO vigibase(R).
Mult Scler. 2025 Oct 8:13524585251377411. doi: 10.1177/13524585251377411.
PubMed Abstract available

AJDINAJ P, Mongay-Ochoa N, Alberich M, Tintore M, et al
Long-term impact of spinal cord reserve on disability accumulation in multiple sclerosis.
Mult Scler. 2025 Oct 7:13524585251378995. doi: 10.1177/13524585251378995.
PubMed Abstract available

SUTHIPHOSUWAN S, Lim TR, Hu Z, Colak E, et al
Choroid plexus enlargement correlates with demyelinating lesions and thalamic atrophy in radiologically isolated syndrome.
Mult Scler. 2025;31:1314-1325.
PubMed Abstract available

FREEDMAN DE, Campbell KA, Feinstein A
Affective reserve in multiple sclerosis.
Mult Scler. 2025;31:1397-1400.
PubMed

REINSBERG HK, Oertel FC, Casillas D, Kaufhold G, et al
Investigating the impact of age on neurodegeneration after optic neuritis in multiple sclerosis using optical coherence tomography.
Mult Scler. 2025;31:1493-1505.
PubMed Abstract available

PAISEY C, Curtin K, Epps SJ, Rice CM, et al
Acute retinal necrosis associated with dimethyl fumarate.
Mult Scler. 2025;31:1506-1508.
PubMed Abstract available

September 2025

GRAY-RONCAL K, Appiah MJ, Zorn K, Smith KC, et al
Increased contact with clinical trial participants may improve confirmed multiple sclerosis relapse detection.
Mult Scler. 2025 Sep 25:13524585251373002. doi: 10.1177/13524585251373002.
PubMed Abstract available

LEAVITT VM, Simani L, Koch M, Morrow SA, et al
The language and memory test: A brief multidomain digital cognitive measure for multiple sclerosis.
Mult Scler. 2025 Sep 25:13524585251366096. doi: 10.1177/13524585251366096.
PubMed Abstract available

RIVIER CA, Xu L, Clocchiatti-Tuozzo S, Zhao H, et al
Differential results of genetic risk scoring for multiple sclerosis in European and African American populations.
Mult Scler. 2025 Sep 24:13524585251377607. doi: 10.1177/13524585251377607.
PubMed Abstract available

UYSAL TAN F, Tan MO
Comment on 'short- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis'.
Mult Scler. 2025 Sep 22:13524585251380003. doi: 10.1177/13524585251380003.
PubMed

CAROLUS B, Dequirez PL, Olivier L, Hafez S, et al
Response to the letter by Uysal Tan and Tan regarding our article "short- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis".
Mult Scler. 2025 Sep 22:13524585251380411. doi: 10.1177/13524585251380411.
PubMed

SHIPLEY J, Beadnall HN, Sanfilippo PG, Horakova D, et al
Disease course after pregnancy in women with progressive multiple sclerosis symptoms.
Mult Scler. 2025 Sep 20:13524585251368248. doi: 10.1177/13524585251368248.
PubMed Abstract available

SALAZAR-CAMELO A, Vega L, Fadlallah Y, Bou Rjeily N, et al
Finite-course ocrelizumab in relapsing multiple sclerosis: Results of two prospective open-label trials with matched controls.
Mult Scler. 2025 Sep 19:13524585251375350. doi: 10.1177/13524585251375350.
PubMed Abstract available

GERNERT JA, Klein M, Schoberl F, Muller KJ, et al
Severe course of tick-borne encephalitis (TBE) in a patient with relapsing multiple sclerosis (MS) treated with ocrelizumab.
Mult Scler. 2025 Sep 11:13524585251369425. doi: 10.1177/13524585251369425.
PubMed Abstract available

TOUBASI A, Hett K, Xu J, Gheen C, et al
Parasagittal dural space and arachnoid granulations morphology in pre-clinical and early clinical multiple sclerosis.
Mult Scler. 2025 Sep 10:13524585251364720. doi: 10.1177/13524585251364720.
PubMed Abstract available

PONZANO M, Fedriga MM, Signori A, Bergamaschi R, et al
Social determinants of health in multiple sclerosis in Italy: A scoping review.
Mult Scler. 2025 Sep 10:13524585251353196. doi: 10.1177/13524585251353196.
PubMed Abstract available

ZHAO-FLEMING HH, Decker PA, Kosel ML, Drucker KL, et al
Genomewide association study of a homogeneous multiple sclerosis cohort: Tumefactive demyelination.
Mult Scler. 2025 Sep 8:13524585251371984. doi: 10.1177/13524585251371984.
PubMed Abstract available

LARONI A, Vigo T, Inglese M, Uccelli A, et al
Immunosenescence in multiple sclerosis: New insights and clinical implications.
Mult Scler. 2025 Sep 2:13524585251367611. doi: 10.1177/13524585251367611.
PubMed Abstract available

LI J, Hutton GJ, Aparasu RR
Prevalence of multiple sclerosis and disease-modifying therapy use in older adults in the United States, 2011-2021.
Mult Scler. 2025 Sep 2:13524585251368687. doi: 10.1177/13524585251368687.
PubMed Abstract available

TOUBASI AA, Graham M, Cutter G, Gheen C, et al
Comparing the macromolecular-to-free pool size ratio and the magnetization transfer ratio for the assessment of myelin injury in early multiple sclerosis.
Mult Scler. 2025 Sep 1:13524585251364766. doi: 10.1177/13524585251364766.
PubMed Abstract available

KOUKOU G, Bartels F, Aigner A, Cleaveland R, et al
Reduced brain volumes in children with radiologically isolated syndrome.
Mult Scler. 2025;31:1195-1204.
PubMed Abstract available

August 2025

BRUNO A, Greco R
Anti-B-cell CAR-T therapy in multiple sclerosis is simply a more profound immunoablation? No.
Mult Scler. 2025 Aug 29:13524585251364144. doi: 10.1177/13524585251364144.
PubMed

MASSEY J, Monif M
Anti-B-cell CAR-T therapy in multiple sclerosis is simply a more profound immunoablation? Commentary.
Mult Scler. 2025 Aug 29:13524585251370085. doi: 10.1177/13524585251370085.
PubMed

DERSCH R, Wiendl H
'Anti-B cell CAR-T therapy in multiple sclerosis is simply a more profound immunoablation': Yes.
Mult Scler. 2025 Aug 29:13524585251364140. doi: 10.1177/13524585251364140.
PubMed

BRIGGS FB, Genuario I, De Nadai AS, Gunzler DD, et al
Predicting suicidal ideation at subsequent clinical encounter in multiple sclerosis patients.
Mult Scler. 2025 Aug 25:13524585251365207. doi: 10.1177/13524585251365207.
PubMed Abstract available

ZHAO DH, Hadley G, Pisa M, Saunders P, et al
Successful alemtuzumab retreatment in multiple sclerosis following previous diffuse alveolar haemorrhage.
Mult Scler. 2025 Aug 20:13524585251365791. doi: 10.1177/13524585251365791.
PubMed Abstract available

KRAJNC N, Ponleitner M, Fottinger F, Leutmezer F, et al
Serum neurofilament light chain and glial fibrillary acidic protein levels are associated with inner retinal layer thinning in multiple sclerosis.
Mult Scler. 2025 Aug 19:13524585251360972. doi: 10.1177/13524585251360972.
PubMed Abstract available

KRAUSE N, Derad C, von Glasenapp B, Riemann-Lorenz K, et al
Digital lifestyle management application (levidex) for empowerment and health behaviour change in early multiple sclerosis - Results of the randomised controlled POWER@MS1 trial.
Mult Scler. 2025 Aug 12:13524585251356410. doi: 10.1177/13524585251356410.
PubMed Abstract available

JOKUBAITIS VG, Alroughani R, Altintas A, Eichau S, et al
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024).
Mult Scler. 2025;31:1088-1101.
PubMed Abstract available

July 2025

AXHAUSEN F, Mrochen A, Winter P, Baumgart R, et al
Disease outcomes following lateral switch among different CD20-antibodies in active multiple sclerosis.
Mult Scler. 2025 Jul 30:13524585251361330. doi: 10.1177/13524585251361330.
PubMed Abstract available

CELLERINO M, Massarotti C, Peluffo C, Sirito T, et al
Relationship between ovarian reserve and disease activity in women with multiple sclerosis.
Mult Scler. 2025 Jul 28:13524585251356384. doi: 10.1177/13524585251356384.
PubMed Abstract available

ASP AJ, Jahanian O, Gill ML, Veith DD, et al
Percutaneous epidural spinal cord stimulation immediately reduces clonus in an individual with multiple sclerosis.
Mult Scler. 2025 Jul 28:13524585251357143. doi: 10.1177/13524585251357143.
PubMed Abstract available

FEYS P, Lamers I, Kos D, Reebye R, et al
Embracing the complexity of rehabilitation in multiple sclerosis empowered by the resolution of the World Health Organization.
Mult Scler. 2025 Jul 23:13524585251356967. doi: 10.1177/13524585251356967.
PubMed Abstract available

COHEN JA, Arnold DL, DeLuca J, Hartung HP, et al
Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials.
Mult Scler. 2025 Jul 23:13524585251355842. doi: 10.1177/13524585251355842.
PubMed Abstract available

LEBRUN-FRENAY C, Okuda DT
High-risk populations should be screened for multiple sclerosis: No.
Mult Scler. 2025 Jul 8:13524585251353025. doi: 10.1177/13524585251353025.
PubMed

BECZEK A, Landt EM, Magyari M, Storr LK, et al
Assessing the association between mortality and clinical follow-up visits in multiple sclerosis.
Mult Scler. 2025 Jul 7:13524585251353079. doi: 10.1177/13524585251353079.
PubMed Abstract available

BOFFA G, Genchi A, Mariottini A, Brittain G, et al
Aggressive MS and Autologous HSCT: A review on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation.
Mult Scler. 2025 Jul 7:13524585251349129. doi: 10.1177/13524585251349129.
PubMed Abstract available

AFFINITO G, Moccia M, Lanzillo R, Marrie RA, et al
Neural networks to estimate multiple sclerosis disability and predict progression using routinely collected healthcare data.
Mult Scler. 2025 Jul 3:13524585251347513. doi: 10.1177/13524585251347513.
PubMed Abstract available

June 2025

CRUZ RIVERA S, Buxhoeveden S, Aiyegbusi OL, Bozinov N, et al
The importance of patient-reported outcomes: A call for their integration in the routine care of patients with multiple sclerosis.
Mult Scler. 2025 Jun 29:13524585251349354. doi: 10.1177/13524585251349354.
PubMed Abstract available

BALSHI A, Dempsey JP, Manning N, Leuenberger G, et al
Malignant melanoma and multiple sclerosis therapies: A disproportionality analysis of the FDA adverse event reporting system.
Mult Scler. 2025 Jun 25:13524585251342725. doi: 10.1177/13524585251342725.
PubMed Abstract available

PORTACCIO E, Betti M, De Meo E, Pasto L, et al
Age-dependent response to initial highly effective treatment in relapsing multiple sclerosis.
Mult Scler. 2025 Jun 19:13524585251345317. doi: 10.1177/13524585251345317.
PubMed Abstract available

ARAB BAFRANI M, Rios V, Kim MJ, Balan A, et al
Gynecological health: A missing link in comprehensive treatment monitoring for multiple sclerosis.
Mult Scler. 2025 Jun 18:13524585251346371. doi: 10.1177/13524585251346371.
PubMed Abstract available

SAHU M, Chomba M, Mortel D, Braun S, et al
Factors associated with delay to diagnosis of multiple sclerosis in Zambia.
Mult Scler. 2025 Jun 17:13524585251344832. doi: 10.1177/13524585251344832.
PubMed Abstract available

BEREK K, Schmidauer M, Bsteh G, Auer M, et al
Kappa free light chain index predicts long-term disease activity and disability accrual in multiple sclerosis.
Mult Scler. 2025 Jun 16:13524585251344807. doi: 10.1177/13524585251344807.
PubMed Abstract available

STEIN C, O'Keeffe F, Brosnan M, Flynn C, et al
Cognitive reserve in multiple sclerosis: The role of depression and fatigue.
Mult Scler. 2025 Jun 11:13524585251338757. doi: 10.1177/13524585251338757.
PubMed Abstract available

MOCCIA M
Clinical commentary to gender-affirming interventions and prognosis in multiple sclerosis.
Mult Scler. 2025 Jun 3:13524585251341177. doi: 10.1177/13524585251341177.
PubMed

NEYAL N, Nathoo N, Cathcart-Rake EJ, Kantarci OH, et al
Gender-affirming interventions and prognosis in multiple sclerosis.
Mult Scler. 2025 Jun 3:13524585251341174. doi: 10.1177/13524585251341174.
PubMed Abstract available

VARLEY J, Beyrouti R, Nicholas R, Dorsey R, et al
A comparison of JC virus assay performance provided with originator and biosimilar natalizumab.
Mult Scler. 2025;31:882-885.
PubMed Abstract available

VUKUSIC S, Hubben F, Gavoille A, Malek Y, et al
Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test?
Mult Scler. 2025;31:877-881.
PubMed Abstract available

GARTHOF S, Schafer S, Elmers J, Schwed L, et al
Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study.
Mult Scler. 2025;31:856-865.
PubMed Abstract available

LEAVITT VM, Fox R, Mostert J, D'Haeseleer M, et al
Cognitive test performance and disease progression in primary and secondary progressive MS: An analysis of the SPRINT-MS study.
Mult Scler. 2025;31:866-876.
PubMed Abstract available

ARNOLD DL, Kolind S, Assemlal HE, Bar-Or A, et al
Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.
Mult Scler. 2025;31:821-832.
PubMed Abstract available

May 2025

NOVAKOVA L, Rosenstein I, Axelsson M, Schoonheim MM, et al
Plateau of practice effects and noise with repeat SDMT testing and in multiple sclerosis.
Mult Scler. 2025 May 31:13524585251344794. doi: 10.1177/13524585251344794.
PubMed Abstract available

VILASECA A, Vidal-Jordana A, Sceppacuercia S, Calderon W, et al
Radiologically isolated syndrome: How could we accurately diagnose a subclinical period of multiple sclerosis?
Mult Scler. 2025 May 30:13524585251332115. doi: 10.1177/13524585251332115.
PubMed Abstract available

FOONG YC, Butzkueven H
Should disease-modifying therapy be discontinued in older patients with stable multiple sclerosis after long-term clinical and radiological stability? - No.
Mult Scler. 2025 May 26:13524585251344805. doi: 10.1177/13524585251344805.
PubMed

ROD BE, Hogestol EA, Torkildsen O, Bjornevik K, et al
Comparative effectiveness of rituximab and cladribine in relapsing-remitting multiple sclerosis: A target trial emulation.
Mult Scler. 2025 May 26:13524585251342727. doi: 10.1177/13524585251342727.
PubMed Abstract available

ROSTON S, Quick MH, Tisavipat N, Rattanathamsakul N, et al
Assessment of increased opening pressure in patients with multiple sclerosis and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder.
Mult Scler. 2025 May 26:13524585251340841. doi: 10.1177/13524585251340841.
PubMed Abstract available

ZANE GK, Sutton A, Brumwell A, Hossain MR, et al
The path to prevention of multiple sclerosis: Considerations for Epstein-Barr virus vaccine-based prevention studies.
Mult Scler. 2025 May 26:13524585251340812. doi: 10.1177/13524585251340812.
PubMed Abstract available

MARRIE RA, Maxwell CJ, Everett K, Zhu F, et al
Health care use preceding pediatric multiple sclerosis: A population-based study from Ontario, Canada.
Mult Scler. 2025 May 23:13524585251338745. doi: 10.1177/13524585251338745.
PubMed Abstract available

MACCARRONE D, Prados F, Ciccarelli O
The relationship between cladribine and reduced regional grey matter volume loss in people with relapsing-remitting multiple sclerosis.
Mult Scler. 2025 May 3:13524585251338772. doi: 10.1177/13524585251338772.
PubMed

LOREFICE L, Zivadinov R
Treating comorbidities in multiple sclerosis is disease-modifying: Yes.
Mult Scler. 2025 May 3:13524585251338750. doi: 10.1177/13524585251338750.
PubMed

GRESELIN M, Lu PJ, Mroczek M, Cerda-Fuertes N, et al
AI-assisted identification of disability patterns within identical EDSS grades.
Mult Scler. 2025;31:677-688.
PubMed Abstract available

FOX RJ, Cohan S, Mao-Draayer Y, Weinstock-Guttman B, et al
Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study.
Mult Scler. 2025;31:706-718.
PubMed Abstract available

April 2025

YALDIZLI O, Benkert P, Achtnichts L, Bar-Or A, et al
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study.
Mult Scler. 2025 Apr 28:13524585251335466. doi: 10.1177/13524585251335466.
PubMed Abstract available

STEPHENS S, Iseyas N, Yeh EA
Physical activity demonstrates protective associations with structural visual metrics in children with multiple sclerosis through time.
Mult Scler. 2025 Apr 28:13524585251335510. doi: 10.1177/13524585251335510.
PubMed Abstract available

PILOTTO S, Pontieri L, Nielsen HH, Rasmussen PV, et al
Pediatric Onset Multiple Sclerosis (POMS): Exploring phenotypic characterization and pubertal influences in modulating the disease activity from the Danish MS Registry (DMSR).
Mult Scler. 2025 Apr 28:13524585251335476. doi: 10.1177/13524585251335476.
PubMed Abstract available

MADILL E, Moreira Ferreira V, Healy B, Zurawski J, et al
Change in serum neurofilament light chain and glial fibrillary acidic protein levels with high-efficacy and low-efficacy early therapy in multiple sclerosis.
Mult Scler. 2025 Apr 28:13524585251335521. doi: 10.1177/13524585251335521.
PubMed Abstract available

FERRAZZANO G, Maccarrone D, Guerra A, Collura A, et al
The effects of gamma-tACS on cognitive impairment in multiple sclerosis: A randomized, double-blind, sham-controlled, pilot study.
Mult Scler. 2025 Apr 26:13524585251333575. doi: 10.1177/13524585251333575.
PubMed Abstract available

GREENWALD MA, Cancel Asencio HG, Dwyer J, Moss A, et al
Differential Validity in the Written, Oral, and Electronic SDMT in Multiple Sclerosis.
Mult Scler. 2025 Apr 24:13524585251330961. doi: 10.1177/13524585251330961.
PubMed Abstract available

KRAJNC N, Fottinger F, Ponleitner M, Kornek B, et al
Diagnostic accuracy of inter-eye difference of ganglion cell layer alone in identifying optic neuritis in multiple sclerosis.
Mult Scler. 2025 Apr 22:13524585251332895. doi: 10.1177/13524585251332895.
PubMed Abstract available

MARRIE RA, Bolton JM, Ling V, Bernstein CN, et al
Risk factors for incident peripartum mental illness in multiple sclerosis.
Mult Scler. 2025 Apr 18:13524585251330109. doi: 10.1177/13524585251330109.
PubMed Abstract available

MACARON G, Farah N, Charbonneau S, Morrow SA, et al
Addressing patient-reported cognitive impairment in multiple sclerosis clinical practice: A challenging endeavor.
Mult Scler. 2025 Apr 18:13524585251334488. doi: 10.1177/13524585251334488.
PubMed Abstract available

FADLALLAH Y, Wang Y, Malik MT, Tian F, et al
Frequency and potential risk factors associated with the development of asymptomatic T2 hyperintense cervical spine lesions on MRI in patients with relapsing-remitting multiple sclerosis.
Mult Scler. 2025 Apr 17:13524585251331405. doi: 10.1177/13524585251331405.
PubMed Abstract available

JENSEN MP, Robles S, Nash MG, May S, et al
Hypnosis and mindfulness audio recordings for reducing fatigue in individuals with multiple sclerosis: A randomized controlled study.
Mult Scler. 2025 Apr 17:13524585251329820. doi: 10.1177/13524585251329820.
PubMed Abstract available

EL AYOUBI NK, Bal MN, Metri N, El Sammak S, et al
Slower retinal thinning over a year predicts continuous NEDA status at follow-up in multiple sclerosis: A longitudinal OCT study.
Mult Scler. 2025 Apr 12:13524585251332499. doi: 10.1177/13524585251332499.
PubMed Abstract available

BSTEH G, Hegen H, Albrecht P, Havla J, et al
Emphasizing complementary in "Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis".
Mult Scler. 2025 Apr 12:13524585251329800. doi: 10.1177/13524585251329800.
PubMed

CHRISTENSEN R, Jolly A, Yam C, Yiannakas MC, et al
Response to letter to the editor: 'Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis'.
Mult Scler. 2025 Apr 12:13524585251329787. doi: 10.1177/13524585251329787.
PubMed

LIU X, Wang Y, Wei N, Zhu W, et al
The characteristics and influencing factors of paramagnetic rim lesions in Chinese MS patients: A 7T MRI study.
Mult Scler. 2025 Apr 12:13524585251328902. doi: 10.1177/13524585251328902.
PubMed Abstract available

REVIE L, Jurjens A, Eveslage M, Trumpelmann S, et al
Suboptimal B-cell depletion is associated with progression independent of relapse activity in multiple sclerosis patients treated with ocrelizumab.
Mult Scler. 2025 Apr 3:13524585251329849. doi: 10.1177/13524585251329849.
PubMed Abstract available

SAYLOR D, Rijke N, McDonell J, Laurson-Doube J, et al
Recommendations for essential medicines for multiple sclerosis in low-resource settings.
Mult Scler. 2025;31:464-473.
PubMed Abstract available

MERLO D, Ja J, Foong YC, Zhu C, et al
Long-term acceptability of MSReactor digital cognitive monitoring among people living with multiple sclerosis.
Mult Scler. 2025 Apr 1:13524585251329035. doi: 10.1177/13524585251329035.
PubMed Abstract available

BARANZINI SE
The Barancik award lecture: Multi-disciplinary research will be the key to stop, restore, and end MS.
Mult Scler. 2025;31:384-391.
PubMed Abstract available

BOBELNA B, Lobjois Q, Croitoru S, Jalkh E, et al
Incidence of optic neuritis among Afro-descendant, a cohort study.
Mult Scler. 2025;31:529-538.
PubMed Abstract available

LAAKSO SM, Oh J, Raufdeen F, Jones A, et al
Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort.
Mult Scler. 2025;31:607-611.
PubMed Abstract available

March 2025

CIAMPI E, Garcia L, Carcamo C, Soler B, et al
Practical issues concerning the use of optical coherence tomography in multiple sclerosis in Latin America: Discussion from 19 centres on behalf of the Foro Latam EM study group.
Mult Scler. 2025 Mar 29:13524585251329159. doi: 10.1177/13524585251329159.
PubMed Abstract available

LEVIT E, Cohen I, Mahajan A, Ulano A, et al
Evaluation of the relationship between brainstem lesions and apnea hypopnea index in patients with multiple sclerosis.
Mult Scler. 2025 Mar 29:13524585251327875. doi: 10.1177/13524585251327875.
PubMed Abstract available

NOROOZI R, Tsai HH, Yu K, Bronson P, et al
Metabolic and lipid alterations in multiple sclerosis linked to disease severity.
Mult Scler. 2025 Mar 27:13524585251325468. doi: 10.1177/13524585251325468.
PubMed Abstract available

LIU X, Zhang C
Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model.
Mult Scler. 2025 Mar 27:13524585251324854. doi: 10.1177/13524585251324854.
PubMed

SIMANI L, Leavitt VM
Response to the letter: Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model.
Mult Scler. 2025 Mar 27:13524585251324872. doi: 10.1177/13524585251324872.
PubMed

BAKIRTZIS C, Dimitriou N, Moysiadis T, El-Wahsh S, et al
Communication deficits in multiple sclerosis: Interactions with cognitive dysfunction and their impact on employment status.
Mult Scler. 2025 Mar 20:13524585251328556. doi: 10.1177/13524585251328556.
PubMed Abstract available

FREEDMAN DE, Oh J, Meza C, Feinstein A, et al
Seizure history and cognitive dysfunction in people with multiple sclerosis.
Mult Scler. 2025 Mar 18:13524585251326841. doi: 10.1177/13524585251326841.
PubMed Abstract available

WILLIAMS J, Marin WM, Wade KJ, Suseno R, et al
Copy number variation at the complement C4 locus is associated with risk for multiple sclerosis.
Mult Scler. 2025 Mar 15:13524585251324850. doi: 10.1177/13524585251324850.
PubMed Abstract available

CAROLUS B, Dequirez PL, Olivier L, Hafez S, et al
Short- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis.
Mult Scler. 2025 Mar 13:13524585251323178. doi: 10.1177/13524585251323178.
PubMed Abstract available

CARVAJAL R, Tur C, Borras-Bermejo B, Saylor D, et al
Vaccination in multiple sclerosis: Tackling challenges and paving the way for effective immunization.
Mult Scler. 2025 Mar 12:13524585251318513. doi: 10.1177/13524585251318513.
PubMed Abstract available

MAILLART E, Rollot F, Leray E, Benyahya L, et al
Pregnancy and birth outcomes in women with multiple sclerosis: Comparison of the RESPONSE study to the general French population.
Mult Scler. 2025;31:324-337.
PubMed Abstract available

ZEYDAN B, Son J, Neyal N, Schwarz CG, et al
Upper cervical spinal cord atrophy in MS: Sex, menopause, and neurodegeneration.
Mult Scler. 2025;31:278-289.
PubMed Abstract available

LEBRUN-FRENAY C
The confavreux lecture: The radiologically isolated syndrome diagnosis, prognosis and perspectives.
Mult Scler. 2025;31:249-256.
PubMed Abstract available

AL GBURI M, Mazzola M, Absinta M, Gaitan MI, et al
Paramagnetic rim lesion formation is predicted by the initial gadolinium-enhancing lesion diameter.
Mult Scler. 2025;31:263-277.
PubMed Abstract available

RAMDANI R, Pique J, Deschamps R, Ciron J, et al
Evaluation of the predictive value of CSF-restricted oligoclonal bands on residual disability and risk of relapse in adult patients with MOGAD: MOGADOC study.
Mult Scler. 2025;31:290-302.
PubMed Abstract available

February 2025

STOGBAUER J, Schegerer V, Berger FK, Schulz-Schaeffer W, et al
Severe coxsackie virus B5 encephalitis mimics autoimmune limbic encephalitis in a young woman under long-term B-cell depletion with ocrelizumab: A case report.
Mult Scler. 2025 Feb 27:13524585251322327. doi: 10.1177/13524585251322327.
PubMed Abstract available

BALSHI A
Climate change and multiple sclerosis: Clinical challenges and strategies.
Mult Scler. 2025 Feb 26:13524585251322664. doi: 10.1177/13524585251322664.
PubMed Abstract available

GOGA JJ, Ginell KM, Ng YT, Ehde DM, et al
Feasibility, reliability, and validity of ambulatory smartphone-administered cognitive tests in multiple sclerosis.
Mult Scler. 2025 Feb 25:13524585251320814. doi: 10.1177/13524585251320814.
PubMed Abstract available

BARRANTES-CEPAS M, Noteboom S, Colato E, Battaglini M, et al
Treatment effects of cladribine tablets on data-driven patterns of regional grey matter atrophy in multiple sclerosis.
Mult Scler. 2025 Feb 25:13524585251314779. doi: 10.1177/13524585251314779.
PubMed Abstract available

DELUCA J
An interdisciplinary approach is necessary in the treatment of cognitive decline in Multiple Sclerosis: Commentary.
Mult Scler. 2025 Feb 25:13524585251315357. doi: 10.1177/13524585251315357.
PubMed

DONKERS SJ, Walker LA
An interdisciplinary approach is necessary in the treatment of cognitive decline in multiple sclerosis - YES.
Mult Scler. 2025 Feb 25:13524585251315344. doi: 10.1177/13524585251315344.
PubMed

SCHOEPS VA, Smith JB, Langer-Gould A
Migraines, the multiple sclerosis prodrome, and multiple sclerosis susceptibility.
Mult Scler. 2025 Feb 19:13524585251318293. doi: 10.1177/13524585251318293.
PubMed Abstract available

LINDBERG S, Sandgren S, Axelsson M, Rosenstein I, et al
Quality of life is decreased in persons with relapsing-remitting multiple sclerosis experiencing progression independent of relapse activity.
Mult Scler. 2025 Feb 18:13524585251318516. doi: 10.1177/13524585251318516.
PubMed Abstract available

KARATSIDIS A, Angelini L, Scaramozza M, Bartholome E, et al
Characterizing gait in people with multiple sclerosis using digital data from smartphone sensors: A proposed framework.
Mult Scler. 2025 Feb 18:13524585251316242. doi: 10.1177/13524585251316242.
PubMed Abstract available

MITRACHE DESAGA AC, Noui Y, Silfverberg T, Carlson K, et al
Patient-reported outcomes of quality of life before and after autologous hematopoietic stem cell transplantation for multiple sclerosis.
Mult Scler. 2025 Feb 17:13524585251315363. doi: 10.1177/13524585251315363.
PubMed Abstract available

SIMONSEN CS, Flemmen HO, Broch L, Brekke K, et al
Reduced childbirth rates in multiple sclerosis from the prodromal phase: Evidence from a population-based cohort study.
Mult Scler. 2025 Feb 17:13524585251315077. doi: 10.1177/13524585251315077.
PubMed Abstract available

VAVASOUR I, Elliott C, Arnold DL, Gaetano L, et al
Presence of slowly expanding lesions in multiple sclerosis predicts progressive demyelination within lesions and normal-appearing tissue over time.
Mult Scler. 2025 Feb 14:13524585251316519. doi: 10.1177/13524585251316519.
PubMed Abstract available

ALBERGONI M, Preziosa P, Meani A, Dallari C, et al
Aerobic capacity moderates the association between cervical cord atrophy and clinical disability in mildly disabled multiple sclerosis patients.
Mult Scler. 2025 Feb 14:13524585251318647. doi: 10.1177/13524585251318647.
PubMed Abstract available

MARRODAN M, Sao Aviles A, Rio J, Cobo-Calvo A, et al
Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies.
Mult Scler. 2025 Feb 10:13524585251316471. doi: 10.1177/13524585251316471.
PubMed Abstract available

VILASECA A, Tintore M, Carbonell-Mirabent P, Rodriguez-Barranco M, et al
Uncovering alternative diagnoses in patients with clinical syndromes suggestive of multiple sclerosis: A transversal study from the prospective Barcelona CIS cohort.
Mult Scler. 2025 Feb 5:13524585251314749. doi: 10.1177/13524585251314749.
PubMed Abstract available

SUMOWSKI JF, Sandry J
Multiple Sclerosis Cognitive Scale (MSCS): A brief psychometrically robust metric of patient-reported cognitive difficulty.
Mult Scler. 2025 Feb 2:13524585241309805. doi: 10.1177/13524585241309805.
PubMed Abstract available

TAUL-MADSEN L, Hvid LG, Riis H, Brolos MK, et al
A head-to-head comparison of the effects of aerobic versus resistance training on physical capacity and physical function in people with multiple sclerosis: Results from the MSBOOST trial.
Mult Scler. 2025;31:174-183.
PubMed Abstract available

CORBOY JR, Fox RJ, Cutter G, Engebretson E, et al
DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial.
Mult Scler. 2025;31:159-173.
PubMed Abstract available

LEBRUN-FRENAY C, Kerbrat S, Okuda DT, Landes-Chateau C, et al
Analysis of healthcare utilization before the diagnosis of radiologically isolated syndrome.
Mult Scler. 2025;31:184-196.
PubMed Abstract available

PATEL AD, Connors A, Esch ME
Ofatumumab-associated colitis: A case report.
Mult Scler. 2025;31:242-245.
PubMed Abstract available

January 2025

MARTIRE MS, Moiola L, Maggi P, Borrelli S, et al
Reliability of paramagnetic rim lesion detection at 1.5T MRI in multiple sclerosis patients.
Mult Scler. 2025 Jan 31:13524585251314358. doi: 10.1177/13524585251314358.
PubMed Abstract available

ACHIRON A, Warszawer Y, Nissan Y, Kerpel A, et al
Positive impact of cladribine tablets on reducing brain atrophy in patients with relapsing-remitting multiple sclerosis: A longitudinal study.
Mult Scler. 2025 Jan 27:13524585251313749. doi: 10.1177/13524585251313749.
PubMed Abstract available

DE ANGELIS F, Ammoscato F, Parker RA, Plantone D, et al
Neurofilament heavy chain in secondary progressive multiple sclerosis.
Mult Scler. 2025 Jan 22:13524585241311212. doi: 10.1177/13524585241311212.
PubMed Abstract available

YILMAZER C, D'haeseleer M, Soler B, Van Wijmeersch B, et al
Assessing pain in multiple sclerosis: Test-retest reliability of patient-reported outcome measures and accuracy of screening tools.
Mult Scler. 2025 Jan 16:13524585241310139. doi: 10.1177/13524585241310139.
PubMed Abstract available

DEL CANTO A, Carcamo C, Garcia L, Aylwin E, et al
Real-world evidence of ocrelizumab in Chilean patients with multiple sclerosis.
Mult Scler. 2025 Jan 6:13524585241309835. doi: 10.1177/13524585241309835.
PubMed Abstract available

WITT L, Dost-Kovalsky K, Friedmann N, Bast N, et al
Ofatumumab-exposed breastfeeding in multiple sclerosis patients.
Mult Scler. 2025 Jan 6:13524585241307165. doi: 10.1177/13524585241307165.
PubMed Abstract available

SALTER A, Lancia S, Cutter GR, Fox RJ, et al
Post-acute sequela of COVID-19 infection in individuals with multiple sclerosis.
Mult Scler. 2025 Jan 3:13524585241310104. doi: 10.1177/13524585241310104.
PubMed Abstract available

SIMANI L, Tozlu C, Lee S, Dworkin J, et al
Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model.
Mult Scler. 2025 Jan 3:13524585241303491. doi: 10.1177/13524585241303491.
PubMed Abstract available

GIOVANNONI G, Boyko A, Correale J, Edan G, et al
Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort.
Mult Scler. 2025;31:44-58.
PubMed Abstract available

MANISCALCO GT, Dinoto A, Foglia MC, Di Battista ME, et al
Epstein-Barr virus infection in patients with MOGAD.
Mult Scler. 2025;31:117-120.
PubMed Abstract available

December 2024

MAGGI G, Altieri M, Risi M, Rippa V, et al
Cognitive reserve predicts long-term cognitive trajectories in relapsing-remitting multiple sclerosis.
Mult Scler. 2024 Dec 27:13524585241302167. doi: 10.1177/13524585241302167.
PubMed Abstract available

BRIGGS FB, Conway DS, Hersh CM, Fitzgerald KC, et al
The onset presentation of multiple sclerosis differs in Hispanic/Latinx Americans compared with non-Hispanic White Americans.
Mult Scler. 2024 Dec 24:13524585241304976. doi: 10.1177/13524585241304976.
PubMed Abstract available

CHRISTENSEN R, Jolly A, Yam C, Yiannakas MC, et al
Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis.
Mult Scler. 2024 Dec 20:13524585241304356. doi: 10.1177/13524585241304356.
PubMed Abstract available

MALLUCCI G, Zimmer A, Sfikas N, Cerda-Fuertes N, et al
Neurostatus-SMARTCARE clinical trial: Enabling health care professionals to assess EDSS for decentralized trials in multiple sclerosis.
Mult Scler. 2024 Dec 20:13524585241305966. doi: 10.1177/13524585241305966.
PubMed Abstract available

CORREALE J, Marrodan M
Live-attenuated vaccines for multiple sclerosis patients living in regions with endemic infections: A complex decision.
Mult Scler. 2024 Dec 18:13524585241305956. doi: 10.1177/13524585241305956.
PubMed Abstract available

NYLANDER A, Sisodia N, Henderson K, Wijangco J, et al
From "invisible" to "audible": Features extracted during simple speech tasks classify patient-reported fatigue in multiple sclerosis.
Mult Scler. 2024 Dec 17:13524585241303855. doi: 10.1177/13524585241303855.
PubMed Abstract available

VAN DAM M, Rottgering JG, Nauta IM, de Jong BA, et al
Understanding the complex network of objectively assessed cognition and self-reported psychological symptoms in people with multiple sclerosis.
Mult Scler. 2024 Dec 9:13524585241302173. doi: 10.1177/13524585241302173.
PubMed Abstract available

KRYSKO KM
Considerations for family planning in adolescent and young adults with multiple sclerosis.
Mult Scler. 2024 Dec 7:13524585241303481. doi: 10.1177/13524585241303481.
PubMed

CHANG G, Stoney S, Narula S
Pregnancy outcomes in adolescent and young adult patients with multiple sclerosis: A case series.
Mult Scler. 2024 Dec 7:13524585241303490. doi: 10.1177/13524585241303490.
PubMed Abstract available

FRAMKE E, Sellebjerg F, Kant M, Stilund M, et al
Risk of hypertension in patients with multiple sclerosis treated with teriflunomide compared to dimethyl fumarate: A nationwide cohort study in Denmark.
Mult Scler. 2024 Dec 4:13524585241299715. doi: 10.1177/13524585241299715.
PubMed Abstract available

JIANG X, McGinley M, Johnston J, Alberts J, et al
A digital version of the nine-hole peg test: Speed may be a more reliable measure of upper-limb disability than completion time in patients with multiple sclerosis.
Mult Scler. 2024 Dec 1:13524585241301854. doi: 10.1177/13524585241301854.
PubMed Abstract available

CHITNIS T, Arnold DL, Quartier P, Chirieac M, et al
Safety, efficacy, and tolerability of alemtuzumab in pediatric patients with active relapsing-remitting multiple sclerosis: The LemKids study.
Mult Scler. 2024 Dec 1:13524585241295554. doi: 10.1177/13524585241295554.
PubMed Abstract available

PORTACCIO E
Toward a holistic approach to multiple sclerosis: The role of social determinants of health.
Mult Scler. 2024 Dec 1:13524585241302684. doi: 10.1177/13524585241302684.
PubMed

LEFORT M, Dejardin O, Berger E, Camdessanche JP, et al
Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France.
Mult Scler. 2024 Dec 1:13524585241289276. doi: 10.1177/13524585241289276.
PubMed Abstract available

CARVAJAL R, Rodriguez-Acevedo B, Garcia-Vasco L, Zabalza A, et al
Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies.
Mult Scler. 2024;30:1788-1801.
PubMed Abstract available

KEVER A, Heuer LB, Simani L, Leavitt VM, et al
Development and initial validation of the Cognitive Change Scale (CCS).
Mult Scler. 2024;30:1815-1824.
PubMed Abstract available

GAITAN MI, Marquez RV, Ayerbe J, Reich DS, et al
Imaging Outcomes for Phase 2 Trials Targeting Compartmentalized Inflammation.
Mult Scler. 2024;30.
PubMed Abstract available

MOTL RW
Randomized Controlled Trials of Rehabilitation in Multiple Sclerosis: Barriers and Unmet Needs.
Mult Scler. 2024;30.
PubMed Abstract available

PILUTTI LA, Donkers SJ
Exercise as a Therapeutic Intervention in Multiple Sclerosis.
Mult Scler. 2024;30.
PubMed Abstract available

MCGINLEY MP
Improving Access to MS Care Through Technology.
Mult Scler. 2024;30.
PubMed Abstract available

BERGSLAND N, Dwyer MG, Zivadinov R
Imaging the Choroid Plexus.
Mult Scler. 2024;30.
PubMed Abstract available

LANGER-GOULD A
Racial and Ethnic Disease Phenotype Differences Are Driven by Genetics: No.
Mult Scler. 2024;30.
PubMed Abstract available

ONTANEDA D, Miron VE
Breaking Barriers in Multiple Sclerosis.
Mult Scler. 2024;30.
PubMed

KOCH MW, Camara-Lemarroy C, Strijbis E, Mostert J, et al
Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MS.
Mult Scler. 2024;30.
PubMed Abstract available

November 2024

LEFORT M, Dejardin O, Berger E, Camdessanche JP, et al
Association between education level and disability progression in patients with multiple sclerosis in France.
Mult Scler. 2024 Nov 30:13524585241289274. doi: 10.1177/13524585241289274.
PubMed Abstract available

KALAITZIDIS G, Ezzedin O, Bacchetti A, Moussa H, et al
Homonymous hemi-macular atrophy in multiple sclerosis.
Mult Scler. 2024 Nov 23:13524585241297816. doi: 10.1177/13524585241297816.
PubMed Abstract available

GANS A, Verrengia EP, Ricchiuti E, Leva S, et al
Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis: Two case reports and comprehensive literature review.
Mult Scler. 2024 Nov 21:13524585241295677. doi: 10.1177/13524585241295677.
PubMed Abstract available

DARVISHI S, Donnachie E, Gasperi C, Hapfelmeier A, et al
Vaccination as a risk factor for pediatric multiple sclerosis: Insights from a retrospective case-control study.
Mult Scler. 2024 Nov 14:13524585241297003. doi: 10.1177/13524585241297003.
PubMed Abstract available

MAGGI P, Absinta M
Emerging MRI biomarkers for the diagnosis of multiple sclerosis.
Mult Scler. 2024 Nov 7:13524585241293579. doi: 10.1177/13524585241293579.
PubMed Abstract available

HOFFMAN EM, Brown L, Jolliffe E, Sechi E, et al
McArdle sign and neck flexion-induced change in central motor conduction in multiple sclerosis.
Mult Scler. 2024 Nov 6:13524585241295868. doi: 10.1177/13524585241295868.
PubMed Abstract available

WITT L, Haben S, Dost-Kovalsky K, Friedmann N, et al
Impact of symptomatic multiple sclerosis therapy on pregnancy outcome.
Mult Scler. 2024 Nov 6:13524585241293363. doi: 10.1177/13524585241293363.
PubMed Abstract available

HOCHSTETLER A, Lehtinen MK
Choroid plexus as a mediator of CNS inflammation in multiple sclerosis.
Mult Scler. 2024 Nov 6:13524585241292974. doi: 10.1177/13524585241292974.
PubMed Abstract available

JIANG Y, Cesta CE, Liu Q, Kingwell E, et al
Exploring the relationship between polycystic ovarian syndrome, testosterone, and multiple sclerosis in women: A nationwide cohort study and genome-wide cross-trait analysis.
Mult Scler. 2024 Nov 6:13524585241292802. doi: 10.1177/13524585241292802.
PubMed Abstract available

TOOROP AA, Wessels MH, Boonkamp L, Gelissen LM, et al
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.
Mult Scler. 2024 Nov 4:13524585241293940. doi: 10.1177/13524585241293940.
PubMed Abstract available

HSU S, Balan A, Bove R
Topical review: Lactation and use of DMTs in women with MS.
Mult Scler. 2024;30:1578-1591.
PubMed Abstract available

October 2024

YOUNG CA, Rog DJ, Sharrack B, Tanasescu R, et al
Physical and psychological aspects of multiple sclerosis: Revisiting the Multiple Sclerosis Impact Scale (MSIS-29).
Mult Scler. 2024 Oct 30:13524585241288393. doi: 10.1177/13524585241288393.
PubMed Abstract available

TREABA CA, Herranz E, Barletta VT, Mehndiratta A, et al
Phenotyping in vivo chronic inflammation in multiple sclerosis by combined (11)C-PBR28 MR-PET and 7T susceptibility-weighted imaging.
Mult Scler. 2024 Oct 22:13524585241284157. doi: 10.1177/13524585241284157.
PubMed Abstract available

Erratum to "Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis" Multiple Sclerosis Journal; 2024: 30(8); 1086-1088. DOI: 10.1177/13524585241260564.
Mult Scler. 2024 Oct 22:13524585241290986. doi: 10.1177/13524585241290986.
PubMed

PALLADINO R, Chataway J, Mathew M, Majeed A, et al
Trajectories and management of vascular risk following the diagnosis of multiple sclerosis: A population-based matched cohort study between 1987 and 2018 in England.
Mult Scler. 2024 Oct 17:13524585241287388. doi: 10.1177/13524585241287388.
PubMed Abstract available

DE NADAI AS, Zamora RJ, Finch A, Miller DM, et al
Multiple sclerosis subgroups: Data-driven clusters based on patient-reported outcomes and a large clinical sample.
Mult Scler. 2024 Oct 17:13524585241282763. doi: 10.1177/13524585241282763.
PubMed Abstract available

VAN LIEROP ZY, Wessels MH, Lekranty WM, Moraal B, et al
Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic.
Mult Scler. 2024 Oct 17:13524585241277044. doi: 10.1177/13524585241277044.
PubMed Abstract available

VLAD B, Neidhart S, Hilty M, Asplund Hogelin K, et al
Intrathecal immune reactivity against Measles-, Rubella-, and Varicella Zoster viruses is associated with cerebrospinal fluid inflammation in multiple sclerosis.
Mult Scler. 2024 Oct 8:13524585241279645. doi: 10.1177/13524585241279645.
PubMed Abstract available

AMEZCUA L, Hamilton RH, Ciccarelli O
The current state of diversity, equity, and inclusion in multiple sclerosis research, clinical trials, and workforce.
Mult Scler. 2024 Oct 8:13524585241286988. doi: 10.1177/13524585241286988.
PubMed

VERCELLINO M, Marasciulo S, Ricotti E, Rolando A, et al
Long-term modifications of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in multiple sclerosis.
Mult Scler. 2024 Oct 7:13524585241284846. doi: 10.1177/13524585241284846.
PubMed Abstract available

September 2024

NESBITT C, Van Der Walt A, Butzkueven H, Devitt B, et al
Multiple sclerosis and cancer: Navigating a dual diagnosis.
Mult Scler. 2024 Sep 30:13524585241274523. doi: 10.1177/13524585241274523.
PubMed Abstract available

BAYOUMI A, Hasan KM, Thomas JA, Yazdani A, et al
Glymphatic dysfunction in multiple sclerosis and its association with disease pathology and disability.
Mult Scler. 2024 Sep 29:13524585241280842. doi: 10.1177/13524585241280842.
PubMed Abstract available

OCAMPO A, Hatami F, Cuklina J, Graham G, et al
Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model.
Mult Scler. 2024 Sep 28:13524585241275471. doi: 10.1177/13524585241275471.
PubMed Abstract available

INOJOSA H, Voigt I, Wenk J, Ferber D, et al
Integrating large language models in care, research, and education in multiple sclerosis management.
Mult Scler. 2024 Sep 23:13524585241277376. doi: 10.1177/13524585241277376.
PubMed Abstract available

JACOBS BM, Schalk L, Tregaskis-Daniels E, Tank P, et al
The relationship between ethnicity and multiple sclerosis characteristics in the United Kingdom: A UK MS Register study.
Mult Scler. 2024 Sep 20:13524585241277018. doi: 10.1177/13524585241277018.
PubMed Abstract available

O'DONNELL E, Schuette A, Waltz M, Aaen G, et al
Patient and family views on research priorities and design of clinical trials and research studies in pediatric multiple sclerosis.
Mult Scler. 2024 Sep 17:13524585241274580. doi: 10.1177/13524585241274580.
PubMed Abstract available

PILLONI G, Lustberg M, Malik M, Feinberg C, et al
Hand functioning in progressive multiple sclerosis improves with tDCS added to daily exercises: A home-based randomized, double-blinded, sham-controlled clinical trial.
Mult Scler. 2024 Sep 13:13524585241275013. doi: 10.1177/13524585241275013.
PubMed Abstract available

LANDI D, Bartolomeo S, Bovis F, Amato MP, et al
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy.
Mult Scler. 2024 Sep 12:13524585241274600. doi: 10.1177/13524585241274600.
PubMed Abstract available

HOLTZER R, Foley FW, Motl RW, Wagshul ME, et al
Brain hemodynamic responses and fall prediction in older adults with multiple sclerosis.
Mult Scler. 2024 Sep 11:13524585241277400. doi: 10.1177/13524585241277400.
PubMed Abstract available

PIEDRABUENA MA, Correale J, Farez MF, Rodriguez Murua S, et al
Telomere length as a biomarker in multiple sclerosis.
Mult Scler. 2024 Sep 9:13524585241273054. doi: 10.1177/13524585241273054.
PubMed Abstract available

LUNEMANN JD, Sao Aviles A, Tintore M, Midaglia L, et al
Cytomegalovirus immune responses are associated with lower serum NfL and disability accumulation risk at multiple sclerosis onset.
Mult Scler. 2024 Sep 9:13524585241274571. doi: 10.1177/13524585241274571.
PubMed Abstract available

ZURRER WE, Cannon AE, Ilchenko D, Gaitan MI, et al
Misdiagnosis and underdiagnosis of multiple sclerosis: A systematic review and meta-analysis.
Mult Scler. 2024 Sep 8:13524585241274527. doi: 10.1177/13524585241274527.
PubMed Abstract available

SARTHOU A, Chretien P, Giorgi L, Chiron A, et al
The kappa free light chains index is an accurate diagnostic biomarker for paediatric multiple sclerosis.
Mult Scler. 2024 Sep 8:13524585241274034. doi: 10.1177/13524585241274034.
PubMed Abstract available

COERVER EM, Kacar S, Ciccarelli O, Sormani MP, et al
Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations.
Mult Scler. 2024 Sep 8:13524585241272938. doi: 10.1177/13524585241272938.
PubMed Abstract available

BRIGGS FB, Gunzler DD, Miller DM, Ontaneda D, et al
Mobility trajectories in multiple sclerosis: A comparative study of timed 25-foot walk and a patient-reported outcome measure.
Mult Scler. 2024 Sep 5:13524585241274607. doi: 10.1177/13524585241274607.
PubMed Abstract available

PETRACCA M, Ruggieri S, Nistri R, Tomasso I, et al
Brain reserve and timing of clinical onset in multiple sclerosis.
Mult Scler. 2024 Sep 5:13524585241272046. doi: 10.1177/13524585241272046.
PubMed Abstract available

TOLJAN K, Daboul L, Raza P, Martin ML, et al
Diagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis.
Mult Scler. 2024 Sep 5:13524585241271988. doi: 10.1177/13524585241271988.
PubMed Abstract available

LANDES-CHATEAU C, Ricigliano VA, Mondot L, Thouvenot E, et al
Choroid plexus enlargement correlates with periventricular pathology but not with disease activity in radiologically isolated syndrome.
Mult Scler. 2024;30:1278-1289.
PubMed Abstract available

CHICO-GARCIA JL, Sainz Amo R, Monreal E, Sainz de la Maza S, et al
Progression independent of relapse activity can be predicted by passively acquired tapping speed through a smartphone for 1 month: A prospective study.
Mult Scler. 2024;30:1341-1349.
PubMed Abstract available

COBO-CALVO A, Tintore M
Prioritizing global strategies to cure MS.
Mult Scler. 2024;30:1239-1241.
PubMed

KRUPP L, O'Neill KA
Monitoring cognitive functioning in MS will trigger anxiety in patients: Yes.
Mult Scler. 2024;30:1252-1254.
PubMed

KLEIN M
Monitoring cognitive functioning in MS will trigger anxiety in patients: No.
Mult Scler. 2024;30:1254-1256.
PubMed

August 2024

BEBO BF JR, Banwell BL, Whitacre CC, Coetzee T, et al
The refined Pathways to Cures Research Roadmap for multiple sclerosis cures.
Mult Scler. 2024 Aug 30:13524585241266483. doi: 10.1177/13524585241266483.
PubMed Abstract available

ZICCARDI S, Guandalini M, Fuchs TA, Calabrese M, et al
The time to include cognition in the multiple sclerosis concept of progression independent from relapse activity is now.
Mult Scler. 2024 Aug 28:13524585241264476. doi: 10.1177/13524585241264476.
PubMed Abstract available

FUCHS TA, Schoonheim MM, Zivadinov R, Dwyer MG, et al
Cognitive progression independent of relapse in multiple sclerosis.
Mult Scler. 2024 Aug 28:13524585241256540. doi: 10.1177/13524585241256540.
PubMed Abstract available

TUR C, Portaccio E
Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive decline.
Mult Scler. 2024 Aug 28:13524585241273037. doi: 10.1177/13524585241273037.
PubMed

RIVERO-DE-AGUILAR A, Perez-Rios M, Mascarenas-Garcia M, Ruano-Ravina A, et al
Discrepancies in the results reported for multiple sclerosis clinical trials: A comparison between ClinicalTrials.gov and peer-reviewed journals.
Mult Scler. 2024 Aug 27:13524585241273089. doi: 10.1177/13524585241273089.
PubMed Abstract available

CICCARESE G, Zanghi A, Herzum A, Fidanzi C, et al
Acute urticaria following ofatumumab injection for multiple sclerosis.
Mult Scler. 2024 Aug 26:13524585241273084. doi: 10.1177/13524585241273084.
PubMed

HARROUD A, Sawcer SJ, Baranzini SE
Genetics of multiple sclerosis severity: The importance of statistical power in replication studies.
Mult Scler. 2024 Aug 14:13524585241264472. doi: 10.1177/13524585241264472.
PubMed

MONTOBBIO N, Carmisciano L, Signori A, Ponzano M, et al
Creating an automated tool for a consistent and repeatable evaluation of disability progression in clinical studies for multiple sclerosis.
Mult Scler. 2024 Aug 14:13524585241243157. doi: 10.1177/13524585241243157.
PubMed Abstract available

KALINCIK T
The era of harmonised disability outcomes in multiple sclerosis.
Mult Scler. 2024 Aug 14:13524585241266517. doi: 10.1177/13524585241266517.
PubMed

CAMPAGNA MP, Lechner-Scott J, Taylor BV, Havrdova EK, et al
Re: Genetics of multiple sclerosis severity: The importance of statistical power in replication studies and Re: From discovery to replication: Power and definitions matter for multiple sclerosis severity.
Mult Scler. 2024 Aug 14:13524585241264469. doi: 10.1177/13524585241264469.
PubMed

LAPUCCI C, Frau J, Cocco E, Coghe G, et al
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study.
Mult Scler. 2024 Aug 14:13524585241266509. doi: 10.1177/13524585241266509.
PubMed Abstract available

BSTEH G, Hegen H, Krajnc N, Fottinger F, et al
Retinal layer thinning for monitoring disease-modifying treatment in relapsing multiple sclerosis-Evidence for applying a rebaselining concept.
Mult Scler. 2024 Aug 7:13524585241267257. doi: 10.1177/13524585241267257.
PubMed Abstract available

CAMPBELL JA, Simpson-Yap S, Taylor BV, van der Mei I, et al
Significantly increasing multiple sclerosis prevalence in Australia from 2010 to 2021.
Mult Scler. 2024 Aug 5:13524585241265890. doi: 10.1177/13524585241265890.
PubMed Abstract available

CAMERON MH, Hildebrand A, Hugos C, Wooliscroft L, et al
A walking aid selection, training, and education program (ADSTEP) to prevent falls in multiple sclerosis: A randomized controlled trial.
Mult Scler. 2024 Aug 5:13524585241265031. doi: 10.1177/13524585241265031.
PubMed Abstract available

DVORAK E, Levy S, Anderson JR, Sumowski JF, et al
Phonemic processing is below expectations and linked to word-finding difficulty in multiple sclerosis.
Mult Scler. 2024 Aug 5:13524585241259648. doi: 10.1177/13524585241259648.
PubMed Abstract available

ROOS I, Sharmin S, Malpas C, Ozakbas S, et al
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
Mult Scler. 2024 Aug 1:13524585241267211. doi: 10.1177/13524585241267211.
PubMed Abstract available

VOSKUHL R
All women with multiple sclerosis should start hormone replacement therapy at menopause unless contraindicated: Yes.
Mult Scler. 2024;30:1107-1109.
PubMed

ZHANG Q, Noyce AJ, Robson J, Giovannoni G, et al
No association between oral contraceptive exposure and subsequent MS: A population-based nested case-control study in primary care.
Mult Scler. 2024;30:1221-1226.
PubMed Abstract available

CHEEMA S, Matharu M
Facial pain in MS: When to think of trigeminal autonomic cephalalgia.
Mult Scler. 2024;30:1230-1231.
PubMed

July 2024

BEBO B, Coetzee T, Gray E, Helme A, et al
The first global landscape analysis of multiple sclerosis research funding.
Mult Scler. 2024 Jul 31:13524585241265961. doi: 10.1177/13524585241265961.
PubMed Abstract available

PROSPERINI L, Ruggieri S, Haggiag S, Tortorella C, et al
Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world context.
Mult Scler. 2024 Jul 31:13524585241266180. doi: 10.1177/13524585241266180.
PubMed Abstract available

SIDHU NK, Proudfoot H, Adan HM, Fawson S, et al
Diversity and inclusion in behavioural intervention trials in multiple sclerosis: A commentary.
Mult Scler. 2024 Jul 26:13524585241248279. doi: 10.1177/13524585241248279.
PubMed

STRIDH P, Huang J, Kockum I
From discovery to replication: Power and definitions matter for multiple sclerosis severity.
Mult Scler. 2024 Jul 26:13524585241265021. doi: 10.1177/13524585241265021.
PubMed

MOHAN SD, Peterson S, Brenton JN, Carmichael SL, et al
Association of nutritional intake with clinical and imaging activity in pediatric multiple sclerosis.
Mult Scler. 2024;30:1056-1065.
PubMed Abstract available

ZEINEDDINE M, Al-Roughani R, Farouk Ahmed S, Khoury S, et al
Safety and effectiveness of disease-modifying therapies after switching from natalizumab.
Mult Scler. 2024;30:1026-1035.
PubMed Abstract available

DE JONG DJ, Strijbis EM, Killestein J
Information from ecological momentary assessments lead to over-medicalization: Commentary.
Mult Scler. 2024;30:972-973.
PubMed

PREZIOSA P, Rocca MA, Filippi M
Information from ecological momentary assessments leads to over-medicalization: No.
Mult Scler. 2024;30:970-972.
PubMed

HOGESTOL EA, Berg-Hansen P
Information from ecological momentary assessments lead to over-medicalization: Yes.
Mult Scler. 2024;30:968-969.
PubMed

LEVIT E, Ren Z, Gonzenbach V, Azevedo CJ, et al
Choroid plexus volume differentiates MS from its mimics.
Mult Scler. 2024;30:1072-1076.
PubMed Abstract available

MEALLI F, Mattei A, Mariottini A, Massacesi L, et al
Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study.
Mult Scler. 2024;30:1077-1080.
PubMed Abstract available

COBAN H
Tick-borne illnesses in patients treated with B-cell depleting agents: Considerations for neurologists.
Mult Scler. 2024;30:1084-1085.
PubMed

MCMURRAN CE, Mukherjee T, Brown JWL, Coles AJ, et al
Bexarotene leads to durable improvements in visual evoked potential latency: A follow-up study of the Cambridge Centre for Myelin Repair One trial.
Mult Scler. 2024;30:1066-1071.
PubMed Abstract available

June 2024

MOROZUMI T, Preziosa P, Meani A, Pessina G, et al
Brain and cervical spinal cord MRI correlates of sensorimotor impairment in patients with multiple sclerosis.
Mult Scler. 2024 Jun 24:13524585241260145. doi: 10.1177/13524585241260145.
PubMed Abstract available

MALLUCCI G, Monti MC, Ponzio M, Borrelli P, et al
Impact of multiple sclerosis comorbidities on quality of life and job activity.
Mult Scler. 2024 Jun 24:13524585241260550. doi: 10.1177/13524585241260550.
PubMed Abstract available

SCARAMOZZA M, Chiesa PA, Zajac L, Sun Z, et al
Konectom cognitive processing speed test enables reliable remote, unsupervised cognitive assessment in people with multiple sclerosis: Exploring the use of substitution time as a novel digital outcome measure.
Mult Scler. 2024 Jun 24:13524585241259650. doi: 10.1177/13524585241259650.
PubMed Abstract available

MAGYARI M
All women with multiple sclerosis should start hormone replacement therapy at menopause unless contraindicated: No.
Mult Scler. 2024 Jun 22:13524585241254987. doi: 10.1177/13524585241254987.
PubMed

PETHERAM K, Dobson R
All women with multiple sclerosis should start hormone replacement therapy at menopause unless contraindicated: Commentary.
Mult Scler. 2024 Jun 22:13524585241254989. doi: 10.1177/13524585241254989.
PubMed

CONTE WL
Addressing LGBTQ+ health equity and disparities in multiple sclerosis: A call for research and action.
Mult Scler. 2024 Jun 19:13524585241263281. doi: 10.1177/13524585241263281.
PubMed Abstract available

MORROW SA, Hancock L
Monitoring cognitive functioning in multiple sclerosis will trigger anxiety in patients: Commentary.
Mult Scler. 2024 Jun 16:13524585241261200. doi: 10.1177/13524585241261200.
PubMed

BALSHI A, Manning N, Dempsey J, Kumbar S, et al
Altered lymphocyte profiles and herpes zoster infections in patients with multiple sclerosis on natalizumab.
Mult Scler. 2024 Jun 16:13524585241260537. doi: 10.1177/13524585241260537.
PubMed Abstract available

KOLSCHE T, Willison AG, Meuth SG, Pawlitzki M, et al
Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis.
Mult Scler. 2024 Jun 15:13524585241260564. doi: 10.1177/13524585241260564.
PubMed

DALLA COSTA G, Leocani L, Pisa M, Croese T, et al
Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres.
Mult Scler. 2024 Jun 14:13524585241260977. doi: 10.1177/13524585241260977.
PubMed Abstract available

KRIJNEN EA, Kouwenhoven RM, Noteboom S, Barkhof F, et al
Subtypes and location of (juxta)cortical lesions relate to cognitive dysfunction in people with multiple sclerosis.
Mult Scler. 2024 Jun 13:13524585241260968. doi: 10.1177/13524585241260968.
PubMed Abstract available

SMETS I, Versteegh M, Huygens S, Wokke B, et al
Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model.
Mult Scler. 2024 Jun 10:13524585241258692. doi: 10.1177/13524585241258692.
PubMed Abstract available

NOVA A, Di Caprio G, Bernardinelli L, Fazia T, et al
Genetic and early life factors influence on time-to-multiple sclerosis diagnosis: A UK Biobank study.
Mult Scler. 2024 Jun 7:13524585241257205. doi: 10.1177/13524585241257205.
PubMed Abstract available

BORRELLI S, Guisset F, Vanden Bulcke C, Stolting A, et al
Enlarged perivascular spaces are associated with brain microangiopathy and aging in multiple sclerosis.
Mult Scler. 2024 Jun 7:13524585241256881. doi: 10.1177/13524585241256881.
PubMed Abstract available

PONZANO M, Signori A, Bellavia A, Carbone A, et al
Race and ethnicity in multiple sclerosis phase 3 clinical trials: A systematic review.
Mult Scler. 2024 Jun 7:13524585241254283. doi: 10.1177/13524585241254283.
PubMed Abstract available

FOSTER MA, Prados F, Collorone S, Kanber B, et al
Improving explanation of motor disability with diffusion-based graph metrics at onset of the first demyelinating event.
Mult Scler. 2024;30:800-811.
PubMed Abstract available

MONTOBBIO N, Bovis F, Signori A, Ponzano M, et al
Therapeutic lag: Is treatment effect delayed in progressive MS?
Mult Scler. 2024;30:843-846.
PubMed Abstract available

PFEUFFER S
Psoriasisform dermatitis following anti-CD20 therapies: Immunologic lessons and management dilemmas.
Mult Scler. 2024;30:897-898.
PubMed

May 2024

AKBARIAN F, Rossi C, Costers L, D'hooghe MB, et al
Stimulus-related modulation in the 1/f spectral slope suggests an impaired inhibition during a working memory task in people with multiple sclerosis.
Mult Scler. 2024 May 20:13524585241253777. doi: 10.1177/13524585241253777.
PubMed Abstract available

MENG D, Sacco R, Disanto G, Widmer F, et al
Memory B cell-guided extended interval dosing of ocrelizumab in multiple sclerosis.
Mult Scler. 2024 May 20:13524585241250199. doi: 10.1177/13524585241250199.
PubMed Abstract available

LEBRUN-FRENAY C, Okuda DT
Time to move past typical syndromes in the diagnosis of multiple sclerosis.
Mult Scler. 2024 May 15:13524585241253519. doi: 10.1177/13524585241253519.
PubMed

WICKLEIN R, Kreitner L, Wild A, Aly L, et al
Retinal small vessel pathology is associated with disease burden in multiple sclerosis.
Mult Scler. 2024 May 15:13524585241247775. doi: 10.1177/13524585241247775.
PubMed Abstract available

NAIZER H, Wozny J, Krause TM, Huson E, et al
Trends in central nervous system-active polypharmacy among people with multiple sclerosis.
Mult Scler. 2024 May 15:13524585241251986. doi: 10.1177/13524585241251986.
PubMed Abstract available

HEWARD KD, Roy-Hewitson C, Solomon AJ
Multiple sclerosis presenting with paroxysmal symptoms: Patients at the limitations of current diagnostic criteria.
Mult Scler. 2024 May 15:13524585241253513. doi: 10.1177/13524585241253513.
PubMed Abstract available

COLLORONE S, Coll L, Lorenzi M, Llado X, et al
Artificial intelligence applied to MRI data to tackle key challenges in multiple sclerosis.
Mult Scler. 2024 May 13:13524585241249422. doi: 10.1177/13524585241249422.
PubMed Abstract available

DAGNEW B, Laslett LL, Honan CA, Blizzard L, et al
The association of comorbidities with sleep quality among Australians with multiple sclerosis: Insights from the Australian Multiple Sclerosis Longitudinal Study.
Mult Scler. 2024 May 13:13524585241248278. doi: 10.1177/13524585241248278.
PubMed Abstract available

ANDERSEN ML, Jolving LR, Iachina M, Stenager E, et al
Children born preterm or small for gestational age to mothers with multiple sclerosis: Do these children have an increased risk of infections in early life?
Mult Scler. 2024 May 8:13524585241249077. doi: 10.1177/13524585241249077.
PubMed Abstract available

PROSPERINI L, Haggiag S
Late-onset multiple sclerosis from a different angle.
Mult Scler. 2024 May 8:13524585241249901. doi: 10.1177/13524585241249901.
PubMed

PORTACCIO E, Grossi P, Bellomi F, Bianchi V, et al
Meaningful cognitive change for the Minimal Assessment of Cognitive Function in Multiple Sclerosis.
Mult Scler. 2024 May 8:13524585241249084. doi: 10.1177/13524585241249084.
PubMed Abstract available

April 2024

FEINSTEIN A
Depression is a core symptom of multiple sclerosis.
Mult Scler. 2024 Apr 30:13524585241245637. doi: 10.1177/13524585241245637.
PubMed

HANCOCK LM
Depression is a core symptom of multiple sclerosis: Yes.
Mult Scler. 2024 Apr 30:13524585241249564. doi: 10.1177/13524585241249564.
PubMed

LEAVITT VM
Depression is a core symptom of multiple sclerosis: NO.
Mult Scler. 2024 Apr 30:13524585241245653. doi: 10.1177/13524585241245653.
PubMed

MANUEL AM, Gottlieb A, Freeman L, Zhao Z, et al
Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data.
Mult Scler. 2024 Apr 25:13524585241240398. doi: 10.1177/13524585241240398.
PubMed Abstract available

BIANCHI A, Cortese R, Prados F, Tur C, et al
Optic chiasm involvement in multiple sclerosis, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease.
Mult Scler. 2024 Apr 22:13524585241240420. doi: 10.1177/13524585241240420.
PubMed Abstract available

NOVAK F, Bajwa HM, Ostergaard K, Berg JM, et al
Extended interval dosing with ocrelizumab in multiple sclerosis.
Mult Scler. 2024 Apr 22:13524585241245296. doi: 10.1177/13524585241245296.
PubMed Abstract available

OKUDA DT, Lebrun-Frenay C
Radiologically isolated syndrome in the spectrum of multiple sclerosis.
Mult Scler. 2024 Apr 15:13524585241245306. doi: 10.1177/13524585241245306.
PubMed Abstract available

CHITNIS T, Banwell B, Kappos L, Arnold DL, et al
Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS.
Mult Scler. 2024 Apr 15:13524585241242050. doi: 10.1177/13524585241242050.
PubMed Abstract available

HEMOND CC, Solomon AJ
Multiple sclerosis can be diagnosed solely with dissemination in space: No.
Mult Scler. 2024 Apr 14:13524585241245297. doi: 10.1177/13524585241245297.
PubMed

MCGINLEY MP, Cohen JA
Multiple sclerosis can be diagnosed solely with dissemination in space: Commentary.
Mult Scler. 2024 Apr 14:13524585241245319. doi: 10.1177/13524585241245319.
PubMed

TOOSY AT, Barkhof F
Multiple sclerosis can be diagnosed solely with dissemination in space: Yes.
Mult Scler. 2024 Apr 14:13524585241245313. doi: 10.1177/13524585241245313.
PubMed

OZTURK B, Taskiran E, Demir S, Tuncer MA, et al
Prevalence and incidence of multiple sclerosis in Turkey: A nationwide epidemiologic study.
Mult Scler. 2024 Apr 14:13524585241245318. doi: 10.1177/13524585241245318.
PubMed Abstract available

SCHNEIDER M, Kramer J, Banks A, Moses H, et al
New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series.
Mult Scler. 2024 Apr 11:13524585241242027. doi: 10.1177/13524585241242027.
PubMed Abstract available

MOCCIA M, Terracciano D, Brescia Morra V, Castaldo G, et al
Neurofilament in clinical practice: Is the multiple sclerosis community ready?
Mult Scler. 2024 Apr 11:13524585241246536. doi: 10.1177/13524585241246536.
PubMed

KWON S, Han KD, Jung JH, Cho EB, et al
Risk of depression and anxiety in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study in South Korea.
Mult Scler. 2024 Apr 1:13524585241237093. doi: 10.1177/13524585241237093.
PubMed Abstract available

ALOISI F, Salvetti M
EBV infection drives MS pathology: Yes.
Mult Scler. 2024;30.
PubMed

CORTESE M, Ascherio A
EBV infection drives MS pathology: Commentary.
Mult Scler. 2024;30.
PubMed

'T HART BA, van Luijn MM
EBV infection drives MS pathology: No.
Mult Scler. 2024;30.
PubMed

TUR C, Battiston M, Yiannakas MC, Collorone S, et al
What contributes to disability in progressive MS? A brain and cervical cord-matched quantitative MRI study.
Mult Scler. 2024;30.
PubMed Abstract available

REEVES JA, Mohebbi M, Wicks T, Salman F, et al
Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years.
Mult Scler. 2024;30.
PubMed Abstract available

KLISTORNER S, Barnett MH, Wang C, Parratt J, et al
Longitudinal enlargement of choroid plexus is associated with chronic lesion expansion and neurodegeneration in RRMS patients.
Mult Scler. 2024;30.
PubMed Abstract available

March 2024

PAPPOLLA A, Auger C, Sao-Aviles A, Tur C, et al
Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs.
Mult Scler. 2024 Mar 29:13524585241240653. doi: 10.1177/13524585241240653.
PubMed Abstract available

SIMPSON AC, Hu C, Mowry EM, Naismith RT, et al
Structural MRI measures are associated with fatigue severity and persistence in a large, real-world cohort of people with multiple sclerosis.
Mult Scler. 2024 Mar 25:13524585241239473. doi: 10.1177/13524585241239473.
PubMed Abstract available

SORENSEN PS, Bramow S, Magyari M, Werdelin L, et al
Torben Fog - A Danish pioneer in a multi-faceted spectrum of multiple sclerosis research.
Mult Scler. 2024 Mar 24:13524585241239506. doi: 10.1177/13524585241239506.
PubMed Abstract available

MAILLART E, Redolfi S, Louapre C, Houot M, et al
Clinical correlates of respiratory disorders in patients with severe multiple sclerosis: A cross-sectional cohort.
Mult Scler. 2024 Mar 22:13524585241238840. doi: 10.1177/13524585241238840.
PubMed Abstract available

CAMPAGNA MP, Havrdova EK, Horakova D, Izquierdo G, et al
No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry.
Mult Scler. 2024 Mar 21:13524585241240406. doi: 10.1177/13524585241240406.
PubMed Abstract available

HJALGRIM H, Rostgaard K
Infectious mononucleosis and risk of multiple sclerosis: Proxy or culprit?
Mult Scler. 2024 Mar 21:13524585241237708. doi: 10.1177/13524585241237708.
PubMed

GOLDACRE R
Risk of multiple sclerosis in individuals with infectious mononucleosis: a national population-based cohort study using hospital records in England, 2003-2023.
Mult Scler. 2024 Mar 21:13524585241237707. doi: 10.1177/13524585241237707.
PubMed Abstract available

JOHNSSON M, Stenberg YT, Farman HH, Blennow K, et al
Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study.
Mult Scler. 2024 Mar 13:13524585241237388. doi: 10.1177/13524585241237388.
PubMed Abstract available

NAKAMURA K, Sun Z, Hara-Cleaver C, Bodhinathan K, et al
Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial.
Mult Scler. 2024 Mar 12:13524585241235055. doi: 10.1177/13524585241235055.
PubMed Abstract available

EHLING R, Seebacher B, Brenneis C
Letter to the editor: Mobile health interventions in multiple sclerosis: A systematic review.
Mult Scler. 2024 Mar 11:13524585241234789. doi: 10.1177/13524585241234789.
PubMed

HILLERT J, Bove R, Haddad LB, Hellwig K, et al
Expert opinion on the use of contraception in people with multiple sclerosis.
Mult Scler. 2024 Mar 8:13524585241228103. doi: 10.1177/13524585241228103.
PubMed Abstract available

APREA MG, Schiavetti I, Portaccio E, Ballerini C, et al
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis.
Mult Scler. 2024 Mar 8:13524585241232266. doi: 10.1177/13524585241232266.
PubMed Abstract available

KUBICKI K, Stefoski D
Iatrogenic myelodysplastic syndrome complicating multiple sclerosis: A case report.
Mult Scler. 2024 Mar 8:13524585241235539. doi: 10.1177/13524585241235539.
PubMed Abstract available

MONTALBAN X, Piasecka-Stryczynska K, Kuhle J, Benkert P, et al
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
Mult Scler. 2024 Mar 4:13524585241234783. doi: 10.1177/13524585241234783.
PubMed Abstract available

GIULIANI G, Zilli C, Caramia F, Di Piero V, et al
SUNCT syndrome secondary to multiple sclerosis: Not only trigeminal neuralgia.
Mult Scler. 2024 Mar 1:13524585241235535. doi: 10.1177/13524585241235535.
PubMed Abstract available

February 2024

AFZAL RM, Romme Christensen J, Gynthersen RMM, Lebech AM, et al
Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis: A case report.
Mult Scler. 2024 Feb 29:13524585241235542. doi: 10.1177/13524585241235542.
PubMed Abstract available

KARI S, Bucciarelli F, Angles T, Oster AC, et al
Increased levels of circulating soluble CD226 in multiple sclerosis.
Mult Scler. 2024 Feb 29:13524585241234489. doi: 10.1177/13524585241234489.
PubMed Abstract available

HEESEN C, Luhmann D
Reply: Mobile health interventions in multiple sclerosis: A systematic review.
Mult Scler. 2024 Feb 29:13524585241234777. doi: 10.1177/13524585241234777.
PubMed

LIM TRU, Kumaran SP, Suthiphosuwan S, Espiritu AI, et al
Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis.
Mult Scler. 2024 Feb 28:13524585241228426. doi: 10.1177/13524585241228426.
PubMed Abstract available

NAKKEN O, Aarseth JH, Wergeland S, Stigum H, et al
BCG vaccination and multiple sclerosis risk: A Norwegian cohort study.
Mult Scler. 2024 Feb 27:13524585241230440. doi: 10.1177/13524585241230440.
PubMed Abstract available

MILLER AE
Dissemination in time as a requirement for diagnosis of multiple sclerosis: Time for a change?
Mult Scler. 2024 Feb 27:13524585241233999. doi: 10.1177/13524585241233999.
PubMed Abstract available

KRIEGER SC, Sinks S, Huang F, Steverson J, et al
The impact of social distancing measures on anti-JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis.
Mult Scler. 2024 Feb 26:13524585241232274. doi: 10.1177/13524585241232274.
PubMed Abstract available

BOAVENTURA M, Sastre-Garriga J, Rimkus CM, Rovira A, et al
T1/T2-weighted ratio: A feasible MRI biomarker in multiple sclerosis.
Mult Scler. 2024 Feb 22:13524585241233448. doi: 10.1177/13524585241233448.
PubMed Abstract available

EMMA C, Vesela P, Kay P, Huseyin H, et al
Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: Case report and literature review.
Mult Scler. 2024 Feb 22:13524585241232277. doi: 10.1177/13524585241232277.
PubMed Abstract available

ERCAN MB, Kocer B, Altiparmak T, Arslan I, et al
Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis.
Mult Scler. 2024 Feb 22:13524585241231655. doi: 10.1177/13524585241231655.
PubMed

JALALEDDINI K, Bermel RA, Talente B, Weinstein D, et al
A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis.
Mult Scler. 2024 Feb 19:13524585241227372. doi: 10.1177/13524585241227372.
PubMed Abstract available

ROCCA MA, D'Amore G, Valsasina P, Tedone N, et al
2.5-Year changes of connectivity dynamism are relevant for physical and cognitive deterioration in multiple sclerosis.
Mult Scler. 2024 Feb 19:13524585241231155. doi: 10.1177/13524585241231155.
PubMed Abstract available

ROVARIS M, Toselli E, Mendozzi L, Di Tella S, et al
Eye movement desensitization and reprocessing for depressed individuals with multiple sclerosis: A pilot study.
Mult Scler. 2024 Feb 19:13524585241230236. doi: 10.1177/13524585241230236.
PubMed Abstract available

HOANG P, Sturnieks DL, Butler A, Chaplin C, et al
A custom-built step exergame training programme to prevent falls in people with multiple sclerosis: A multicentre randomised controlled trial.
Mult Scler. 2024 Feb 16:13524585241229360. doi: 10.1177/13524585241229360.
PubMed Abstract available

COLLONGUES N, Durand-Dubief F, Lebrun-Frenay C, Audoin B, et al
Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society.
Mult Scler. 2024 Feb 15:13524585231223880. doi: 10.1177/13524585231223880.
PubMed Abstract available

PATEL S, Rafferty S, Aquino L, Chadha S, et al
VISIBL-MS: A bilingual educational framework to increase awareness of early multiple sclerosis.
Mult Scler. 2024 Feb 15:13524585241228739. doi: 10.1177/13524585241228739.
PubMed Abstract available

KVISTAD CE, Lehmann AK, Kvistad SAS, Holmoy T, et al
Autologous hematopoietic stem cell transplantation for multiple sclerosis: Long-term follow-up data from Norway.
Mult Scler. 2024 Feb 12:13524585241231665. doi: 10.1177/13524585241231665.
PubMed Abstract available

MOTL RW, Russell DI, Pilutti LA, Metse AP, et al
Drop-out, adherence, and compliance in randomized controlled trials of exercise training in multiple sclerosis: Short report.
Mult Scler. 2024 Feb 9:13524585241229332. doi: 10.1177/13524585241229332.
PubMed Abstract available

BELLUCCI G, Buscarinu MC, Renie R, Rinaldi V, et al
Disentangling multiple sclerosis phenotypes through Mendelian disorders: A network approach.
Mult Scler. 2024 Feb 9:13524585241227119. doi: 10.1177/13524585241227119.
PubMed Abstract available

ZIAEI A, Solomon O, Casper TC, Waltz M, et al
Gene-environment interactions: Epstein-Barr virus infection and risk of pediatric-onset multiple sclerosis.
Mult Scler. 2024 Feb 9:13524585231224685. doi: 10.1177/13524585231224685.
PubMed Abstract available

GILMARTIN CG, Hoyle N, Garjani A, Dixon T, et al
Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis.
Mult Scler. 2024 Feb 7:13524585231225711. doi: 10.1177/13524585231225711.
PubMed Abstract available

MCGINLEY MP, Manouchehrinia A
The landscape of multiple sclerosis registries: Strengths and limitations.
Mult Scler. 2024 Feb 6:13524585241228746. doi: 10.1177/13524585241228746.
PubMed

VUKUSIC S, Bourre B, Casey R, Deiva K, et al
The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years-Protocol, recruitment status, and baseline characteristics.
Mult Scler. 2024;30:216-226.
PubMed Abstract available

GHAJARZADEH M, Fitzgerald KC, Mowry EM, Nourbakhsh B, et al
Association between demographics, socioeconomics, and disease-related factors and the perception of stigma in people with MS.
Mult Scler. 2024;30:238-246.
PubMed Abstract available

SCHNEIDER R, Brand-Arzamendi K, Reynold Lim T, Lee LE, et al
Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim lesions in people with radiologically isolated syndrome.
Mult Scler. 2024;30:156-165.
PubMed Abstract available

LANGDON D
Neuropsychological assessment in MS is outdated and in need for innovation: NO.
Mult Scler. 2024;30:152-153.
PubMed

January 2024

NAKAMURA K, Thoomukuntla B, Bena J, Cohen JA, et al
Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.
Mult Scler. 2024 Jan 29:13524585231224702. doi: 10.1177/13524585231224702.
PubMed Abstract available

SWITAL M, Drouin J, Miranda S, Bakchine S, et al
Use of multiple sclerosis disease-modifying therapies during pregnancy in France: Nationwide study between 2010 and 2021.
Mult Scler. 2024 Jan 27:13524585231223395. doi: 10.1177/13524585231223395.
PubMed Abstract available

MISCIOSCIA A, Treaba CA, Barletta VT, Herranz E, et al
White matter paramagnetic rim and non-rim lesions share a periventricular gradient in multiple sclerosis: A 7-T imaging study.
Mult Scler. 2024 Jan 27:13524585231224681. doi: 10.1177/13524585231224681.
PubMed Abstract available

HIRT J, Janiaud P, Dublin P, Nicoletti GJ, et al
Use of pragmatic randomized trials in multiple sclerosis: A systematic overview.
Mult Scler. 2024 Jan 22:13524585231221938. doi: 10.1177/13524585231221938.
PubMed Abstract available

CAMERLINGO S, Rubinstein F, Celia Ysrraelit M, Correale J, et al
Clinical impact of gender and age at onset on disease trajectory in primary progressive multiple sclerosis patients.
Mult Scler. 2024 Jan 21:13524585231219138. doi: 10.1177/13524585231219138.
PubMed Abstract available

JEANTIN L, Januel E, Labauge P, Maillart E, et al
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.
Mult Scler. 2024 Jan 21:13524585231218149. doi: 10.1177/13524585231218149.
PubMed Abstract available

TENI FS, Machado A, Fink K, Gyllensten H, et al
Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden.
Mult Scler. 2024 Jan 19:13524585231225929. doi: 10.1177/13524585231225929.
PubMed Abstract available

VIDAL-JORDANA A, Sastre-Garriga J, Tintore M, Rovira A, et al
Optic nerve topography in multiple sclerosis diagnostic criteria: Existing knowledge and future directions.
Mult Scler. 2024 Jan 19:13524585231225848. doi: 10.1177/13524585231225848.
PubMed Abstract available

TOOROP AA, Noteboom S, Steenwijk MD, Gravendeel JW, et al
Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.
Mult Scler. 2024 Jan 18:13524585231225855. doi: 10.1177/13524585231225855.
PubMed Abstract available

DAS J, Rog DJ, Middleton R, Rodgers JW, et al
University education facilitates uptake of disease-modifying therapies for multiple sclerosis: A community-based study using the UK MS Register.
Mult Scler. 2024 Jan 17:13524585231221411. doi: 10.1177/13524585231221411.
PubMed Abstract available

PORTACCIO E, Iaffaldano P
Maternal smoking and multiple sclerosis risk in offspring: A further clue of prenatal environmental triggers.
Mult Scler. 2024 Jan 11:13524585231224667. doi: 10.1177/13524585231224667.
PubMed

FRAMKE E, Thygesen LC, Malmborg M, Schou M, et al
Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: A nationwide cohort study of 2095 patients in Denmark.
Mult Scler. 2024 Jan 11:13524585231221415. doi: 10.1177/13524585231221415.
PubMed Abstract available

MOTYL J
Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and sensitive approaches beyond simple cut-offs.
Mult Scler. 2024 Jan 9:13524585231221409. doi: 10.1177/13524585231221409.
PubMed

MORROW SA
Response to letter to the editor "Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and sensitive approaches beyond simple cut-offs".
Mult Scler. 2024 Jan 9:13524585231221412. doi: 10.1177/13524585231221412.
PubMed

VENET M, Lepine A, Maarouf A, Biotti D, et al
Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis.
Mult Scler. 2024 Jan 2:13524585231223069. doi: 10.1177/13524585231223069.
PubMed Abstract available

VAN LAETHEM D, Denissen S, Costers L, Descamps A, et al
The Finger Dexterity Test: Validation study of a smartphone-based manual dexterity assessment.
Mult Scler. 2024;30:121-130.
PubMed Abstract available

HUGOS CL, Joos SK, Perumean-Chaney SE, Cutter GR, et al
Stretching is not essential for managing MS spasticity: A randomized controlled trial.
Mult Scler. 2024;30:89-102.
PubMed Abstract available

DE GIER M, Beckerman H, Twisk JW, Knoop H, et al
Effectiveness of a blended booster programme for the long-term outcome of cognitive behavioural therapy for MS-related fatigue: A randomized controlled trial.
Mult Scler. 2024;30:71-79.
PubMed Abstract available

WRIGHT SL, Thompson AJ
Managing patients with late-onset neutropenia during treatment with ocrelizumab.
Mult Scler. 2024;30:134.
PubMed

KOCH-HENRIKSEN NI, Thygesen LC, Sorensen PS, Magyari M, et al
Using instrumental variables to correct for bias in real-world cohort studies of the effects of disease-modifying treatment in MS.
Mult Scler. 2024;30:113-120.
PubMed Abstract available

December 2023

PARCIAK T, Geys L, Helme A, van der Mei I, et al
Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force.
Mult Scler. 2023 Dec 23:13524585231216004. doi: 10.1177/13524585231216004.
PubMed Abstract available

DOBSON R, Holden D, Vickaryous N, Bestwick J, et al
A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis.
Mult Scler. 2023 Dec 22:13524585231215268. doi: 10.1177/13524585231215268.
PubMed Abstract available

NAISMITH RT, Cohen JA, Bar-Or A, Comi G, et al
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.
Mult Scler. 2023 Dec 21:13524585231216854. doi: 10.1177/13524585231216854.
PubMed Abstract available

TAZZA F, Schiavi S, Leveraro E, Cellerino M, et al
Clinical and radiological correlates of apathy in multiple sclerosis.
Mult Scler. 2023 Dec 14:13524585231217918. doi: 10.1177/13524585231217918.
PubMed Abstract available

DABOUL L, O'Donnell CM, Amin M, Rodrigues P, et al
A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis.
Mult Scler. 2023 Dec 13:13524585231214360. doi: 10.1177/13524585231214360.
PubMed Abstract available

DALLA COSTA G, Nos C, Zabalza A, Buron M, et al
A wearable device perspective on the standard definitions of disability progression in multiple sclerosis.
Mult Scler. 2023 Dec 12:13524585231214362. doi: 10.1177/13524585231214362.
PubMed Abstract available

BRUCE JM, Cozart JS, Shook RP, Befort C, et al
Modifying diet and exercise in multiple sclerosis (MoDEMS): A randomized controlled trial for behavioral weight loss in adults with multiple sclerosis and obesity.
Mult Scler. 2023;29:1860-1871.
PubMed Abstract available

SACCO S, Virupakshaiah A, Papinutto N, Schoeps VA, et al
Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease.
Mult Scler. 2023;29:1736-1747.
PubMed Abstract available

LUBLIN FD
Worsening MS-A reappraisal of how we characterize the MS disease course.
Mult Scler. 2023;29:1699-1700.
PubMed

SAMADZADEH S, Olesen MN, Wirenfeldt M, Moller S, et al
Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects.
Mult Scler. 2023;29:1721-1735.
PubMed Abstract available

PROSCHMANN U, Mueller-Enz M, Woopen C, Katoul Al Rahbani G, et al
Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination.
Mult Scler. 2023;29:1849-1859.
PubMed Abstract available

MORROW SA, Weinstock ZL, Mirmosayyeb O, Conway D, et al
Detecting isolated cognitive relapses in persons with MS.
Mult Scler. 2023;29:1786-1794.
PubMed Abstract available

November 2023

MATTIESING RM, Kramer E, Strijbis EM, Brouwer I, et al
Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes.
Mult Scler. 2023 Nov 29:13524585231212879. doi: 10.1177/13524585231212879.
PubMed Abstract available

ZHAO T, Taylor BV, Campbell JA, Palmer AJ, et al
The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022.
Mult Scler. 2023 Nov 24:13524585231213230. doi: 10.1177/13524585231213230.
PubMed Abstract available

MONTEIRO IR, Moccia M
Mobile health interventions in multiple sclerosis: Bringing empowerment into clinical practice.
Mult Scler. 2023 Nov 20:13524585231214879. doi: 10.1177/13524585231214879.
PubMed

CASTANO-AMORES C, Nieto-Gomez P
The crossroads of multiple sclerosis and cancer: Urgent call for clinical direction.
Mult Scler. 2023 Nov 20:13524585231214171. doi: 10.1177/13524585231214171.
PubMed

LADAKIS DC, Reyes-Mantilla MI, Gadani SP, Mace JW, et al
Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis.
Mult Scler. 2023 Nov 20:13524585231213164. doi: 10.1177/13524585231213164.
PubMed Abstract available

NIELSEN NM, Frisch M, Gortz S, Stenager E, et al
Smoking during pregnancy and risk of multiple sclerosis in offspring and mother: A Danish nationwide register-based cohort study.
Mult Scler. 2023 Nov 19:13524585231208310. doi: 10.1177/13524585231208310.
PubMed Abstract available

BROCHET B, Solari A, Lechner-Scott J, Piehl F, et al
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
Mult Scler. 2023 Nov 18:13524585231205962. doi: 10.1177/13524585231205962.
PubMed Abstract available

NICHOLSON S, Russo AW, Brewer K, Bien H, et al
The effect of ibudilast on thalamic volume in progressive multiple sclerosis.
Mult Scler. 2023 Nov 10:13524585231204710. doi: 10.1177/13524585231204710.
PubMed Abstract available

BOU RJEILY N, Fitzgerald KC, Mowry EM
Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity.
Mult Scler. 2023 Nov 9:13524585231208311. doi: 10.1177/13524585231208311.
PubMed Abstract available

AMEZCUA L, Robers MV, Soneji D, Manouvakhova O, et al
Inclusion of optic neuritis in dissemination in space improves the performance of McDonald 2017 criteria in Hispanic people with suspected multiple sclerosis.
Mult Scler. 2023 Nov 9:13524585231209016. doi: 10.1177/13524585231209016.
PubMed Abstract available

ZICCARDI S, Fuchs T, Dwyer MG, Zivadinov R, et al
Cognitive phenotypes predict response to restorative cognitive rehabilitation in multiple sclerosis.
Mult Scler. 2023 Nov 9:13524585231208331. doi: 10.1177/13524585231208331.
PubMed Abstract available

VAN KEMPEN ZL, van Dam KP, Keijser JB, Stalman EW, et al
Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.
Mult Scler. 2023 Nov 9:13524585231207761. doi: 10.1177/13524585231207761.
PubMed Abstract available

FEINSTEIN A
The CogEx trial - Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis: A randomised, blinded, sham-controlled trial.
Mult Scler. 2023 Nov 2:13524585231210178. doi: 10.1177/13524585231210178.
PubMed

CHASE E, Chen V, Martin K, Lane M, et al
A low-fat diet improves fatigue in multiple sclerosis: Results from a randomized controlled trial.
Mult Scler. 2023;29:1659-1675.
PubMed Abstract available

WEINSTOCK ZL, Jaworski M 3rd, Dwyer MG, Jakimovski D, et al
Auditory Test of Processing Speed: Preliminary validation of a smartphone-based test of mental speed.
Mult Scler. 2023;29:1646-1658.
PubMed Abstract available

WISHART M, Everest MR, Morrow SA, Rose J, et al
Establishing the consistency of a voice recognition symbol digit modalities test analogue.
Mult Scler. 2023;29:1676-1679.
PubMed Abstract available

BOCCIA VD, Saitta L, Inglese M, Lapucci C, et al
Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient.
Mult Scler. 2023;29:1688-1692.
PubMed Abstract available

October 2023

ONTANEDA D, Amezcua L
Re-thinking race and geography in multiple sclerosis.
Mult Scler. 2023 Oct 31:13524585231205969. doi: 10.1177/13524585231205969.
PubMed

SINGER BA, Arnold DL, Drulovic J, Freedman MS, et al
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Mult Scler. 2023 Oct 31:13524585231205708. doi: 10.1177/13524585231205708.
PubMed Abstract available

HEESEN C, Berger T, Riemann-Lorenz K, Krause N, et al
Mobile health interventions in multiple sclerosis: A systematic review.
Mult Scler. 2023 Oct 28:13524585231201089. doi: 10.1177/13524585231201089.
PubMed Abstract available

PORWAL MH, Obeidat AZ
A closer look at reported colitis in association with multiple sclerosis treatments.
Mult Scler. 2023 Oct 28:13524585231205964. doi: 10.1177/13524585231205964.
PubMed

LEARMONTH YC, P Herring M, Russell DI, Pilutti LA, et al
Safety of exercise training in multiple sclerosis: An updated systematic review and meta-analysis.
Mult Scler. 2023 Oct 26:13524585231204459. doi: 10.1177/13524585231204459.
PubMed Abstract available

RAMARI C, Awadia Z, Bansi J, Casey B, et al
The MoxFo initiative - outcomes: Outcome measures in studies of exercise training in multiple sclerosis; scoping review of reviews and classification according to the ICF framework.
Mult Scler. 2023 Oct 26:13524585231204451. doi: 10.1177/13524585231204451.
PubMed Abstract available

DALGAS U, Riemenschneider M, Gold SM, Kalron A, et al
The MoXFo initiative - study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis.
Mult Scler. 2023 Oct 26:13524585231204456. doi: 10.1177/13524585231204456.
PubMed Abstract available

MANSOUBI M, Learmonth YC, Mayo N, Collet J, et al
The MoXFo Initiative: Using consensus methodology to move forward towards internationally shared vocabulary in multiple sclerosis exercise research.
Mult Scler. 2023 Oct 26:13524585231204460. doi: 10.1177/13524585231204460.
PubMed Abstract available

ROSENKRANZ SC, Ploughman M, Hvid LG, Zimmer P, et al
The MoxFo initiative-Mechanisms of action: Biomarkers in multiple sclerosis exercise studies.
Mult Scler. 2023 Oct 26:13524585231204453. doi: 10.1177/13524585231204453.
PubMed Abstract available

MOTL RW, Casey B, Learmonth YC, Latimer-Cheung A, et al
The MoXFo initiative - adherence: Exercise adherence, compliance and sustainability among people with multiple sclerosis: An overview and roadmap for research.
Mult Scler. 2023 Oct 26:13524585231204446. doi: 10.1177/13524585231204446.
PubMed Abstract available

ZHANG Y, Atkinson J, Burd CE, Graves J, et al
Biological aging in multiple sclerosis.
Mult Scler. 2023 Oct 25:13524585231204122. doi: 10.1177/13524585231204122.
PubMed Abstract available

BEREK K, Hegen H, Auer M, Barket R, et al
Odour discrimination and identification as a biomarker of long-term disability worsening in multiple sclerosis.
Mult Scler. 2023 Oct 18:13524585231201093. doi: 10.1177/13524585231201093.
PubMed Abstract available

KOCH MW, Moral E, Brieva L, Mostert J, et al
Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.
Mult Scler. 2023 Oct 13:13524585231202320. doi: 10.1177/13524585231202320.
PubMed Abstract available

DARVISHI S, Donnachie E, Gasperi C, Hapfelmeier A, et al
Vaccination frequency in people newly diagnosed with multiple sclerosis.
Mult Scler. 2023 Oct 13:13524585231199084. doi: 10.1177/13524585231199084.
PubMed Abstract available

REYES S, Otero-Romero S
Rethinking vaccination in multiple sclerosis: The way forward.
Mult Scler. 2023 Oct 3:13524585231204126. doi: 10.1177/13524585231204126.
PubMed

LAPUCCI C, Boccia VD, Sirito T, Cellerino M, et al
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series.
Mult Scler. 2023 Oct 3:13524585231204121. doi: 10.1177/13524585231204121.
PubMed Abstract available

TIEPPO EMS, Silva GD, Silva TFFD, Araujo RS, et al
Misdiagnosis in multiple sclerosis in a Brazilian reference center: Clinical, radiological, laboratory profile and failures in the diagnostic process-Cohort study.
Mult Scler. 2023 Oct 3:13524585231199323. doi: 10.1177/13524585231199323.
PubMed Abstract available

JACOBER SLS, Disanto G, Sacco R, Meng D, et al
Interplay between age and disease-modifying treatments in influencing infection risk in multiple sclerosis.
Mult Scler. 2023 Oct 3:13524585231199820. doi: 10.1177/13524585231199820.
PubMed Abstract available

UHER T, Adzima A, Srpova B, Noskova L, et al
Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences.
Mult Scler. 2023;29.
PubMed Abstract available

WU Y, Geraldes R, Jurynczyk M, Palace J, et al
Double-negative neuromyelitis optica spectrum disorder.
Mult Scler. 2023;29.
PubMed Abstract available

THOMPSON AJ, Moccia M, Amato MP, Calabresi PA, et al
Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community.
Mult Scler. 2023;29.
PubMed Abstract available

September 2023

ANDERSON JR, Fitzgerald KC, Murrough JW, Katz Sand IB, et al
Depression symptoms and cognition in multiple sclerosis: Longitudinal evidence of a specific link to executive control.
Mult Scler. 2023 Sep 29:13524585231198746. doi: 10.1177/13524585231198746.
PubMed Abstract available

CERDA-FUERTES N, Stoessel M, Mickeliunas G, Pless S, et al
Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis.
Mult Scler. 2023 Sep 29:13524585231198760. doi: 10.1177/13524585231198760.
PubMed Abstract available

VERCELLINO M, Costantini G, Cogoni M, Lequio L, et al
Association of MRI leptomeningeal enhancement with disability worsening in progressive multiple sclerosis: A clinical and post-mortem study.
Mult Scler. 2023 Sep 23:13524585231199031. doi: 10.1177/13524585231199031.
PubMed Abstract available

FREEDMAN DE, Krysko KM, Feinstein A
Intimate partner violence and multiple sclerosis.
Mult Scler. 2023 Sep 21:13524585231197926. doi: 10.1177/13524585231197926.
PubMed Abstract available

CARVAJAL R, Tur C, Martinez-Gomez X, Bollo L, et al
A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients.
Mult Scler. 2023 Sep 20:13524585231200303. doi: 10.1177/13524585231200303.
PubMed Abstract available

MORALES-RODRIGUEZ D, Anderson A, Nylander A, Hsu S, et al
Well-being at midlife: Correlates of mental health in ambulatory menopausal women with multiple sclerosis.
Mult Scler. 2023 Sep 16:13524585231197056. doi: 10.1177/13524585231197056.
PubMed Abstract available

KRAJNC N, Schmidbauer V, Leinkauf J, Haider L, et al
Paramagnetic rim lesions lead to pronounced diffuse periplaque white matter damage in multiple sclerosis.
Mult Scler. 2023 Sep 15:13524585231197954. doi: 10.1177/13524585231197954.
PubMed Abstract available

BOSE G, Healy BC, Barro C, Moreira Ferreira VF, et al
Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis.
Mult Scler. 2023 Sep 15:13524585231198751. doi: 10.1177/13524585231198751.
PubMed Abstract available

MARTIN SJ, Brand-Arzamendi K, Saab G, Muccilli A, et al
GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis.
Mult Scler. 2023 Sep 12:13524585231195861. doi: 10.1177/13524585231195861.
PubMed Abstract available

MOGHAVEM N, Castaneda GDR, Chatfield AJ, Amezcua L, et al
The impact of medical insurance on health care access and quality for people with multiple sclerosis in the United States: A scoping review.
Mult Scler. 2023 Sep 12:13524585231197275. doi: 10.1177/13524585231197275.
PubMed Abstract available

WANG Y, Bou Rjeily N, Koshorek J, Grkovski R, et al
Clinical and radiologic characteristics associated with multiple sclerosis misdiagnosis at a tertiary referral center in the United States.
Mult Scler. 2023 Sep 12:13524585231196795. doi: 10.1177/13524585231196795.
PubMed Abstract available

BRUNO A, Buttari F, Dolcetti E, Azzolini F, et al
Distinct intrathecal inflammatory signatures following relapse and anti-COVID-19 mRNA vaccination in multiple sclerosis.
Mult Scler. 2023 Sep 12:13524585231197928. doi: 10.1177/13524585231197928.
PubMed Abstract available

HAUSER SL, Zielman R, Das Gupta A, Xi J, et al
Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
Mult Scler. 2023 Sep 11:13524585231195346. doi: 10.1177/13524585231195346.
PubMed Abstract available

DEJONGE SR, DuBose NG, Pilutti LA, Motl RW, et al
Arterial stiffness in persons with multiple sclerosis and controls: Does aerobic fitness account for group differences?
Mult Scler. 2023 Sep 11:13524585231199030. doi: 10.1177/13524585231199030.
PubMed Abstract available

August 2023

HARDY TA
Pseudocystic demyelination in multiple sclerosis.
Mult Scler. 2023 Aug 25:13524585231193365. doi: 10.1177/13524585231193365.
PubMed

CLUSE F, Fenouil T, Vukusic S, Ducray F, et al
Pseudocystic inflammatory demyelinating lesions in multiple sclerosis: A clinical, radiological, and pathological description.
Mult Scler. 2023 Aug 25:13524585231193345. doi: 10.1177/13524585231193345.
PubMed Abstract available

BAR-OR A, Cross AH, Cunningham AL, Hyvert Y, et al
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor.
Mult Scler. 2023 Aug 25:13524585231192460. doi: 10.1177/13524585231192460.
PubMed Abstract available

RAIMO S, Santangelo G, Cropano M, Gaita M, et al
Comparing face-to-face and videoconference assessment of the Brief Repeatable Battery of Neuropsychological Tests in people with multiple sclerosis.
Mult Scler. 2023 Aug 21:13524585231192469. doi: 10.1177/13524585231192469.
PubMed Abstract available

BALSHI A, Saart E, Pandeya S, Dempsey J, et al
High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate.
Mult Scler. 2023 Aug 12:13524585231189641. doi: 10.1177/13524585231189641.
PubMed Abstract available

FAN JH, Alexander J, Poole S, Wijangco J, et al
Characteristics of multiple sclerosis and demyelinating disease in an Asian American population.
Mult Scler. 2023 Aug 7:13524585231188486. doi: 10.1177/13524585231188486.
PubMed Abstract available

MARRIE RA, Bernstein CN, Dolovich C, Bolton JM, et al
Within-person fluctuations over three years in depression, anxiety, fatigue, and health-related quality of life in multiple sclerosis.
Mult Scler. 2023 Aug 3:13524585231190771. doi: 10.1177/13524585231190771.
PubMed Abstract available

NAKAMURA K, Zheng Y, Mahajan KR, Cohen JA, et al
Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.
Mult Scler. 2023 Aug 3:13524585231187289. doi: 10.1177/13524585231187289.
PubMed Abstract available

WESSELS MH, Van Lierop ZY, Noteboom S, Strijbis EM, et al
Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
Mult Scler. 2023 Aug 2:13524585231188625. doi: 10.1177/13524585231188625.
PubMed Abstract available

TAYLOR LA, Mhizha-Murira JR, Law G, Evangelou N, et al
Understanding who benefits most from cognitive rehabilitation for multiple sclerosis: A secondary data analysis.
Mult Scler. 2023 Aug 1:13524585231189470. doi: 10.1177/13524585231189470.
PubMed Abstract available

COTE SE, Wagshul ME, Foley FW, Lipton ML, et al
Caudate volume and symptoms of apathy in older adults with multiple sclerosis.
Mult Scler. 2023 Aug 1:13524585231188096. doi: 10.1177/13524585231188096.
PubMed Abstract available

GRAY E, Amjad A, Robertson J, Beveridge J, et al
Enhancing involvement of people with multiple sclerosis in clinical trial design.
Mult Scler. 2023;29:1162-1173.
PubMed Abstract available

SORMANI MP, Chataway J, Kent DM, Marrie RA, et al
Assessing heterogeneity of treatment effect in multiple sclerosis trials.
Mult Scler. 2023;29:1158-1161.
PubMed Abstract available

MARRIE RA, Sormani MP, Apap Mangion S, Bovis F, et al
Improving the efficiency of clinical trials in multiple sclerosis.
Mult Scler. 2023;29:1136-1148.
PubMed Abstract available

FINLAYSON M, Al-Mashita L, Sandhu R
Participant diversity in clinical trials of rehabilitation interventions for people with multiple sclerosis: A scoping review.
Mult Scler. 2023;29:1149-1157.
PubMed Abstract available

MARRIE RA, Chataway J, Bierer BE, Finlayson M, et al
Enhancing diversity of clinical trial populations in multiple sclerosis.
Mult Scler. 2023;29:1174-1185.
PubMed Abstract available

FINLAYSON M, Feys P, Dalgas U, Kos D, et al
Intermediate outcomes for clinical trials of multiple sclerosis rehabilitation interventions: Conceptual and practical considerations.
Mult Scler. 2023;29:1186-1194.
PubMed Abstract available

GIOVANNONI G
Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary.
Mult Scler. 2023;29:1068-1069.
PubMed

STRIJBIS E, Koch MW, de Jong BA
Quality of life should be the primary outcome for disease modifying therapy trials in MS-No.
Mult Scler. 2023;29:1066-1067.
PubMed

GOVEROVER Y, Chiaravalloti N
Quality of life should be the primary outcome for disease-modifying therapy trials in MS-Yes.
Mult Scler. 2023;29:1064-1065.
PubMed

COHEN M, Thomel-Rocchi O, Siva A, Okuda DT, et al
Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study.
Mult Scler. 2023;29:1099-1106.
PubMed Abstract available

July 2023

CAVALLA P, Vercellino M
May Mediterranean diet contribute to reduce risk of multiple sclerosis?
Mult Scler. 2023 Jul 29:13524585231190342. doi: 10.1177/13524585231190342.
PubMed

GUNZLER DD, De Nadai AS, Miller DM, Ontaneda D, et al
Long-term trajectories of ambulatory impairment in multiple sclerosis.
Mult Scler. 2023 Jul 28:13524585231187521. doi: 10.1177/13524585231187521.
PubMed Abstract available

JAWORSKI MG 3RD, Gillies JK, Youngs M, Wojcik C, et al
Predicting employment deterioration with the Processing Speed Test (PST) and SDMT in multiple sclerosis.
Mult Scler. 2023 Jul 28:13524585231187283. doi: 10.1177/13524585231187283.
PubMed Abstract available

GOVEROVER Y, Amber S, John D
Assessing everyday functional activity in cognitively impaired people with multiple sclerosis: The use of Actual Reality(TM).
Mult Scler. 2023 Jul 26:13524585231185048. doi: 10.1177/13524585231185048.
PubMed Abstract available

DE GIER M, Beckerman H, Twisk J, Knoop H, et al
Blended versus face-to-face cognitive behavioural therapy for severe fatigue in patients with multiple sclerosis: A non-inferiority RCT.
Mult Scler. 2023 Jul 25:13524585231185462. doi: 10.1177/13524585231185462.
PubMed Abstract available

TITBALL RW, Lewis N, Nicholas R
Is Clostridium perfringens epsilon toxin associated with multiple sclerosis?
Mult Scler. 2023 Jul 22:13524585231186899. doi: 10.1177/13524585231186899.
PubMed Abstract available

COHEN JA
Commentary: Solomon AJ et al. Differential diagnosis of suspected multiple sclerosis: An updated consensus approach. Lancet Neurol (in press).
Mult Scler. 2023 Jul 20:13524585231188097. doi: 10.1177/13524585231188097.
PubMed

BOLES GS, Hillert J, Ramanujam R, Westerlind H, et al
The familial risk and heritability of multiple sclerosis and its onset phenotypes: A case-control study.
Mult Scler. 2023 Jul 12:13524585231185258. doi: 10.1177/13524585231185258.
PubMed Abstract available

ORLANDO CM, Perez CA, Agyei P, Elsehety M, et al
Social determinants of health and disparate disability accumulation in a cohort of Black, Hispanic, and White patients with multiple sclerosis.
Mult Scler. 2023 Jul 12:13524585231185046. doi: 10.1177/13524585231185046.
PubMed Abstract available

SIPILA JO, Viitala M, Hanninen A, Soilu-Hanninen M, et al
Exposure to systemic antibiotics in outpatient care and the risk of multiple sclerosis.
Mult Scler. 2023 Jul 10:13524585231185045. doi: 10.1177/13524585231185045.
PubMed Abstract available

NEYAL N, Keegan BM, Kantarci OH, Zeydan B, et al
Coexistence of multiple sclerosis and spinocerebellar ataxia type-8.
Mult Scler. 2023 Jul 3:13524585231180549. doi: 10.1177/13524585231180549.
PubMed Abstract available

KLINEOVA S, Farber RS, DeAngelis T, Leung T, et al
Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: An observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2).
Mult Scler. 2023;29:990-1000.
PubMed Abstract available

ZALOUM SA, Wood CH, Tank P, Upcott M, et al
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination.
Mult Scler. 2023;29:979-989.
PubMed Abstract available

REEVES JA, Weinstock Z, Zivadinov R, Dwyer MG, et al
Paramagnetic rim lesions are associated with greater incidence of relapse and worse cognitive recovery following relapse.
Mult Scler. 2023;29:1033-1038.
PubMed Abstract available

HANCOCK LM, Galioto R, Samsonov A, Busch RM, et al
A taxonomic approach to cognitive diagnostics is viable and achievable in MS.
Mult Scler. 2023;29:1040-1042.
PubMed

June 2023

HE AH, Manouchehrinia A, Glaser A, Ciccarelli O, et al
Association between clinic-level quality of care and patient-level outcomes in multiple sclerosis.
Mult Scler. 2023 Jun 30:13524585231181578. doi: 10.1177/13524585231181578.
PubMed Abstract available

ALFREDSSON L, Olsson T, Hedstrom AK
Inverse association between Mediterranean diet and risk of multiple sclerosis.
Mult Scler. 2023 Jun 27:13524585231181841. doi: 10.1177/13524585231181841.
PubMed Abstract available

JIANG X, Shen C, Teunissen CE, Wessels M, et al
Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation.
Mult Scler. 2023 Jun 15:13524585231176732. doi: 10.1177/13524585231176732.
PubMed Abstract available

SMOOT K, Marginean H, Gervasi-Follmar T, Chen C, et al
Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).
Mult Scler. 2023 Jun 15:13524585231175284. doi: 10.1177/13524585231175284.
PubMed Abstract available

OTERO-ROMERO S, Lebrun-Frenay C, Reyes S, Amato MP, et al
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
Mult Scler. 2023 Jun 9:13524585231168043. doi: 10.1177/13524585231168043.
PubMed Abstract available

NYLANDER AN, Singh J, Poole S, Anderson A, et al
Clinical course of multiple sclerosis and patient experiences during breast cancer treatment.
Mult Scler. 2023 Jun 8:13524585231175975. doi: 10.1177/13524585231175975.
PubMed Abstract available

DELAVAL S, Dequirez PL, Hentzen C, Baron M, et al
Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation-A study from the neuro-urology committee o
Mult Scler. 2023 Jun 2:13524585231174580. doi: 10.1177/13524585231174580.
PubMed Abstract available

LUBLIN FD, Krieger SC
MS becomes a treatable disease: 30 years later.
Mult Scler. 2023;29:789-792.
PubMed Abstract available

REDENBAUGH V, Chia NH, Cacciaguerra L, McCombe JA, et al
Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS.
Mult Scler. 2023;29:799-808.
PubMed Abstract available

LEBRUN-FRENAY C, Okuda DT
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Yes.
Mult Scler. 2023;29:793-795.
PubMed

INGLESE M, Amato MP
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary.
Mult Scler. 2023;29:797-798.
PubMed

SMETS I
Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated - NO.
Mult Scler. 2023;29:795-797.
PubMed

HUMMERT MW, Stern C, Paul F, Duchow A, et al
Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study).
Mult Scler. 2023;29:819-831.
PubMed Abstract available

May 2023

BANWELL B
Pediatric multiple sclerosis: The 2022 ECTRIMS lecture.
Mult Scler. 2023 May 30:13524585231171047. doi: 10.1177/13524585231171047.
PubMed Abstract available

APREA MG, Schiavetti I, Portaccio E, Ballerini C, et al
Sars-CoV2 infection in pregnant women with multiple sclerosis.
Mult Scler. 2023 May 26:13524585231176174. doi: 10.1177/13524585231176174.
PubMed Abstract available

ALSHEHRI E, Cohen JA, Ontaneda D, Nakamura K, et al
The impact of cigarette smoking on cognitive processing speed and brain atrophy in multiple sclerosis.
Mult Scler. 2023 May 19:13524585231172490. doi: 10.1177/13524585231172490.
PubMed Abstract available

VIRUPAKSHAIAH A, Ladakis DC, Nourbakhsh B, Bhargava P, et al
Several serum lipid metabolites are associated with relapse risk in pediatric-onset multiple sclerosis.
Mult Scler. 2023 May 18:13524585231171517. doi: 10.1177/13524585231171517.
PubMed Abstract available

VALENTINE TR, Kratz AL, Kaplish N, Chervin RD, et al
Sleep-disordered breathing and neurocognitive function in multiple sclerosis: Differential associations across cognitive domains.
Mult Scler. 2023 May 17:13524585231169465. doi: 10.1177/13524585231169465.
PubMed Abstract available

CAPUANO R, Prosperini L, Altieri M, Lorefice L, et al
Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs.
Mult Scler. 2023 May 11:13524585231167515. doi: 10.1177/13524585231167515.
PubMed Abstract available

SAUL AM, Taylor BV, Blizzard L, Simpson-Yap S, et al
A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort study.
Mult Scler. 2023 May 6:13524585231167739. doi: 10.1177/13524585231167739.
PubMed Abstract available

KOLIND S, Gaetano L, Assemlal HE, Bernasconi C, et al
Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging.
Mult Scler. 2023;29:741-747.
PubMed Abstract available

April 2023

MARRIE RA
The Barancik lecture: Comorbidity in multiple sclerosis-Looking backward, looking forward.
Mult Scler. 2023 Apr 26:13524585231167740. doi: 10.1177/13524585231167740.
PubMed Abstract available

FINK K, Gorczyca A, Alping P, Englund S, et al
Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study.
Mult Scler. 2023 Apr 18:13524585231161492. doi: 10.1177/13524585231161492.
PubMed Abstract available

RODRIGUEZ LLORIAN E, Zhang W, Khakban A, Michaux K, et al
Employment status, productivity loss, and associated factors among people with multiple sclerosis.
Mult Scler. 2023 Apr 15:13524585231164295. doi: 10.1177/13524585231164295.
PubMed Abstract available

ELLIOTT C, Rudko DA, Arnold DL, Fetco D, et al
Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis.
Mult Scler. 2023 Apr 10:13524585231162262. doi: 10.1177/13524585231162262.
PubMed Abstract available

PALLADINO R, Marrie RA, Majeed A, Chataway J, et al
Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study.
Mult Scler. 2023 Apr 7:13524585231164296. doi: 10.1177/13524585231164296.
PubMed Abstract available

GIOVANNONI G, Boyko A, Correale J, Edan G, et al
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
Mult Scler. 2023 Apr 3:13524585231161494. doi: 10.1177/13524585231161494.
PubMed Abstract available

SATYANARAYAN S, Cutter G, Krieger S, Cofield S, et al
The impact of relapse definition and measures of durability on MS clinical trial outcomes.
Mult Scler. 2023;29.
PubMed Abstract available

WITTAYER M, Weber CE, Kittel M, Platten M, et al
Cerebrospinal fluid-related tissue damage in multiple sclerosis patients with iron rim lesions.
Mult Scler. 2023;29.
PubMed Abstract available

KLISTORNER S, Van der Walt A, Barnett MH, Butzkueven H, et al
Choroid plexus volume is enlarged in clinically isolated syndrome patients with optic neuritis.
Mult Scler. 2023;29.
PubMed Abstract available

ROTSTEIN DL, Wolfson C, Carruthers R, Freedman MS, et al
A national case-control study investigating demographic and environmental factors associated with NMOSD.
Mult Scler. 2023;29.
PubMed Abstract available

TOHYAMA S, Oh J, Timm M, Cheng JC, et al
Should trigeminal neuralgia be considered a clinically isolated syndrome?
Mult Scler. 2023;29.
PubMed Abstract available

ROMAN S
A journey with no roadmap-The need for validated criteria of the MS prodrome.
Mult Scler. 2023;29.
PubMed Abstract available

March 2023

OTTO C, Schwarz T, Jeworowski LM, Schmidt ML, et al
Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations.
Mult Scler. 2023 Mar 28:13524585231161253. doi: 10.1177/13524585231161253.
PubMed Abstract available

SIMON S, Nauta IM, Hillebrand A, Schoonheim MM, et al
Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis.
Mult Scler. 2023 Mar 25:13524585231159817. doi: 10.1177/13524585231159817.
PubMed Abstract available

GHEZZI A, Neuteboom RF
The contribution of neurofilament light chain to better characterize pediatric multiple sclerosis (editorial on: Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized T
Mult Scler. 2023 Mar 23:13524585231161148. doi: 10.1177/13524585231161148.
PubMed

SCHREINER T, Wilson-Murphy M, Mendelt-Tillema J, Waltz M, et al
Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2.
Mult Scler. 2023 Mar 23:13524585231151948. doi: 10.1177/13524585231151948.
PubMed Abstract available

MARRODAN M, Piedrabuena MA, Gaitan MI, Fiol MP, et al
Performance of McDonald 2017 multiple sclerosis diagnostic criteria and evaluation of genetic ancestry in patients with a first demyelinating event in Argentina.
Mult Scler. 2023 Mar 21:13524585231157276. doi: 10.1177/13524585231157276.
PubMed Abstract available

MOTL RW, Kidwell-Chandler A, Sandroff BM, Pilutti LA, et al
Primary results of a phase-III, randomized controlled trial of the Behavioral Intervention for increasing Physical Activity in Multiple Sclerosis project.
Mult Scler. 2023;29:415-426.
PubMed Abstract available

KUHLE J, Chitnis T, Banwell B, Tardieu M, et al
Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
Mult Scler. 2023;29:385-394.
PubMed Abstract available

TOOROP AA, Steenhuis M, Loeff FC, Weijers SS, et al
Fingerprick blood samples to measure serum natalizumab concentrations.
Mult Scler. 2023;29:457-460.
PubMed Abstract available

February 2023

DARUWALLA C, Shaygannejad V, Ozakbas S, Havrdova EK, et al
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Mult Scler. 2023 Feb 27:13524585231151951. doi: 10.1177/13524585231151951.
PubMed Abstract available

October 2021

MHANNA E, Nouchi A, Louapre C, De Paz R, et al
Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination.
Mult Scler. 2021;27:1794-1798.
PubMed Abstract available

DE MOL CL, Bruijstens AL, Jansen PR, Dremmen M, et al
Prevalence of radiologically isolated syndrome in a pediatric population-based cohort: A longitudinal description of a rare diagnosis.
Mult Scler. 2021;27:1790-1793.
PubMed Abstract available

CAPUANO R, Zubizarreta I, Alba-Arbalat S, Sepulveda M, et al
Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability.
Mult Scler. 2021;27:1706-1716.
PubMed Abstract available

ALEXANDER S, Peryer G, Gray E, Barkhof F, et al
Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review.
Mult Scler. 2021;27:1643-1656.
PubMed Abstract available

September 2021

IAFFALDANO P, Lucisano G, Butzkueven H, Hillert J, et al
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network.
Mult Scler. 2021;27:1543-1555.
PubMed Abstract available

DALLA COSTA G, Croese T, Pisa M, Finardi A, et al
CSF extracellular vesicles and risk of disease activity after a first demyelinating event.
Mult Scler. 2021;27:1606-1610.
PubMed Abstract available

SCHNEIDER-HOHENDORF T, Schulte-Mecklenbeck A, Ostkamp P, Janoschka C, et al
High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients.
Mult Scler. 2021;27:1491-1496.
PubMed Abstract available

COHEN M, Mondot L, Bucciarelli F, Pignolet B, et al
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.
Mult Scler. 2021;27:1556-1563.
PubMed Abstract available

THRUE C, Riemenschneider M, Hvid LG, Stenager E, et al
Time matters: Early-phase multiple sclerosis is accompanied by considerable impairments across multiple domains.
Mult Scler. 2021;27:1477-1485.
PubMed Abstract available

August 2021

YAVARPOUR-BALI H, Ghasemi-Kasman M
The role of inflammasomes in multiple sclerosis.
Mult Scler. 2021;27:1323-1331.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.